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ABSTRACT 
 
SARA HANNA: HIF1α and HIF2α independently activate SRC to promote 
melanoma invasion and metastasis 
(Under the direction of Dr. William Kim) 
 
Melanoma incidence is increasing at an epidemic rate of 3% per year.  
When caught early, the disease is easily curable with surgical removal of the 
primary tumor.  However, melanoma is notable for its propensity to metastasize, 
the leading cause of death in cancer patients.  Here we study the role of the 
hypoxia-inducible factors in the malignant progression of melanoma, both in vivo, 
in a genetically engineered mouse model of metastatic melanoma, and in vitro, in 
human melanoma cell lines.  The hypoxia-inducible factor (HIF) family of 
transcription factors are upregulated in melanoma by key oncogenic drivers and 
transactivate genes involved in cancer initiation, progression, and metastases.  
We show that inactivation of either Hif1α or Hif2α abrogates regional lymph node 
metastasis in a Pten-deficient, Braf-mutant genetically engineered mouse model 
of melanoma without affecting primary tumor formation. HIF1α and HIF2α drive 
melanoma cell line invasion and invadopodia formation and mediate these 
effects through the activation of SRC, through PDGFRα and FAK respectively, 
and by coordinating ECM degradation via MT1-MMP and MMP2 expression.
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These results establish the importance of HIFs in melanoma progression and 
demonstrate that HIF1α and HIF2α activate independent transcriptional 
programs that promote metastasis by coordinately regulating cell invasion and 
ECM remodeling
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Chapter I 
 
Melanoma:  The Disease and Its Genetics 
 
 
Melanoma is a cancer of melanocytes, melanin producing cells located at 
the epidermal / dermal junction of the skin.  These cells produce melanin, the 
pigment found in skin, eyes, and hair.  Exposure to ultraviolet (UV) light from the 
sun increases melanogenesis, or the production of melanin, and this increase in 
melanin protects the skin from damage by absorbing the UV light (Agar & Young, 
2005).  The number of people diagnosed with melanoma has been increasing 
epidemically at almost 3% per year in the past thirty years (Krapcho, Neyman, 
Aminou, & Howlader, 2009).  With advancements in screening and early 
detection, as well as increased public knowledge of the disease, melanoma has 
become the sixth most common form of cancer in the United States.  When 
detected early, melanoma can usually be cured with surgical removal of the 
primary tumor and limited to no adjuvant therapy.  However, if diagnosed at a 
later stage, and particularly with metastatic disease, up until recently there have 
been very few treatment options.  Recent scientific discoveries uncovering the 
genetic drivers of melanoma have led to improvements in the treatment of 
metastatic melanoma with targeted therapy.
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A.  Melanoma Development  
 Melanocytes are derived from neural crest cells.  These are transient, 
multipotent cells that migrate during embryogenesis to give rise to multiple cell 
types – including smooth muscle, peripheral and enteric neurons, glia, and 
melanocytes.  Once situated in the epidermis, the proliferation of melanocytes 
remains the under tight control of keratinocytes through direct epidermal-specific 
cell-cell contact though E-cadherin.  Melanocytes only proliferate after stimulation 
by paracrine factors, such as hepatocyte growth factor (HGF), platelet-derived 
growth factor (PDGF), and endothelin-1 (ET-1), secreted by keratinocytes (Haass 
& Herlyn, 2005).  It is through the acquisition of multiple mutations within the 
DNA (deoxyribonucleic acid) of the melanocyte that the cell escapes this tight 
regulation and becomes dysplastic and, ultimately, cancerous. 
 The transformation of a melanocyte into melanoma is believed to occur 
through the acquisition of multiple mutations, usually through UV-induced DNA 
damage (Figure 1).  Once such pathway hypothesized is that an initial oncogenic 
mutation occurs within a member of the RAS (Ras sarcoma) pathway.  The most 
common RAS pathway mutations in melanoma are BRAFV600E (occurring in ~50-
66% of all melanomas (Davies et al., 2002; Maldonado et al., 2003)), NRASQ61R 
(occurring in ~13-25% of all melanomas (Ball et al., 1994; Curtin et al., 2005; van 
't Veer et al., 1989)), and HRASG12V (occurring in 1-7% of all melanomas (Forbes 
et al., 2008; Jafari et al., 1995; Nogueira et al., 2010)).  In normal human 
melanocytes, ectopic introduction of BRAFV600E or NRASQ61R in vitro leads to 
cellular senescence, an irreversible form of cell cycle arrest (Bansal & Nikiforov, 
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2010).  This oncogene-induced senescence (OIS) is a major barrier to oncogenic 
transformation.  Benign nevi, which are considered to be non-proliferative 
melanocytic lesions, represent one of the best in vivo examples of OIS.  
BRAFV600E mutations are found in 60% of benign nevi and are thought to result in 
the initial increase in proliferation of melanocytic cells followed by induction of cell 
cycle arrest and senescence (Pollock et al., 2003). 
 
Figure 1. The Initiation and Progression of Melanoma.  Activation 
mutations of the RAS/RAF pathway occur in normal skin exposed to UV 
radiation.  Oncogene induced senescence is overcome by additional 
mutations, such as loss of the tumor suppressor p16INK4a resulting in a 
melanoma undergoing RGP.   The melanoma cells undergo more mutations to 
initiate VGP, which is associated with metastasis.  Increased expression of 
genes associated with metastasis, such as TWIST1, CD200, and HIF1α, and 
HIF2α are seen in metastatic melanoma. 
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 In order to develop fully into a melanoma, the cells must acquire additional 
alterations or mutations that allow them to overcome OIS.  Loss of p16INK4a or 
activation of the MAPK, PI3K/AKT, and Notch signaling pathways have been 
shown to be important for OIS escape and melanocyte transformation (Slipicevic 
& Herlyn, 2012).  With this transformation, the nevus becomes dysplastic and 
begins to superficially spread along the epidermal basal layer but it remains in 
situ and lacks the capacity to invade the dermis and metastasize.  This is 
generally known as the radial growth phase (RGP).  These cells then acquire 
more mutations that allow them to invade into the dermis in what is known as the 
vertical growth phase (VGP).  From this stage, the cells are more able to spread 
throughout the body, metastasizing to lymph nodes as well as distant organs, 
such as the lung, liver, brain, and bone. 
 
B.  Histiologic Types of Melanoma 
 There are four basic categories of melanoma: superficial spreading 
melanoma (SSM), lentigo maligna (LM), acral lentiginous melanoma (ALM), and 
nodular melanoma (NM) (Table 1).  Superficial spreading melanoma is the most 
common, accounting for about 70% of all diagnosed cases.  This type of 
melanoma, as its name suggests, grows along the top layer of the skin before 
penetrating more deeply. While SSM can be found anywhere on the body, it is 
most commonly found on sun exposed areas of the skin such as the trunk in 
men, the legs of women, and on the upper back of both.  Lentigo maligna, 
accounting for 10% of all diagnosed cases, is a melanoma in situ that consists of 
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malignant cells but does not show invasive growth.  It typically progresses very 
slowly and can remain non-invasive for years.  Once LM begins to grow 
vertically, and invades down into the dermis, it is called lentigo maligna 
melanoma, though this only occurs in about 2-5% of patients.  Acral lentiginous 
melanoma, while accounting for only 5% of all diagnosed cases of melanoma, is 
the most common form of melanoma in Asians and African-Americans.  It is 
commonly found on the palms, soles, under nails, and in oral mucosa.  Unlike 
other forms of melanoma, ALM does not appear to be linked to UV exposure.  
Finally, nodular melanoma is the second most common form of melanoma, 
accounting for about 15% of all diagnosed cases.  It is the most aggressive form 
of melanoma and tends to grow more rapidly in thickness (vertically) than in 
diameter (radially).  NM generally do arise from a pre-existing mole and appear in 
a spot where a lesion did previously not exist (James, Berger, & Elston, 2011). 
 
Melanomas can also be classified based on site of occurrence, level of 
sun exposure, and expression of mutations.  BRAF mutations can be found in 
Table 1: Clinical Subtypes of Melanoma 
TYPE OF 
MELANOMA 
% OF ALL 
MELANOMAS 
COMMON LOCATION 
Superficial Spreading 70 Any sun-exposed area, most 
commonly the back and 
lower legs among women 
Lentigo Maligna 10 Any sun-exposed area 
Acral Lentiginous 5 Soles, palms, under nails, 
mucous membranes 
Nodular 15 Any site 
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melanomas that develop on skin with limited sun exposure.  Patients presenting 
with BRAF mutations often have many nevi.   Melanomas without mutations in 
BRAF or RAS have frequent copy number increases and overexpression of 
cyclin D1 or CDK4 (cyclin dependent kinase 4), genes that are downstream of 
BRAF.  This could be important in treating patients as those with amplification of 
these genes may not respond well to BRAF inhibitors as the drug is targeting too 
far upstream of the mutated pathway.  KIT mutations can generally be found in 
melanomas occurring on chronically exposed skin, such as the lower dorsal arms 
or the head and neck and these patients tend to have relatively few nevi (Curtin 
et al., 2005).  The discovery of specific genetic mutations occurring within 
melanomas located in certain areas of the body will enable screening patients 
more quickly for treatment with therapies that can best target their specific tumor.   
 
C.  Melanoma Staging 
 Melanoma is most lethal form of skin cancer.  While melanoma accounts 
for less than 5% of skin cancer cases, due to its propensity to metastasize, it is 
responsible for 75% of all skin cancer related deaths.  In 2009 the American Joint 
Committee on Cancer (AJCC) set forth an official guideline for the clinical staging 
of melanoma.  The staging system is based on the TNM system where T 
describes the size of the original or primary tumor and whether it has invaded 
into nearby tissue, N describes the regional lymph nodes that are involved, and 
M describes distant metastasis (Balch et al., 2009). 
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Melanoma stages are also based on defining characteristics of the primary 
melanoma and its metastases:  tumor thickness, known as Breslow’s thickness; 
the presence or absence of tumor ulceration; the number of metastatic lymph 
nodes; mitosis within the primary tumor; whether metastasis to the lymph node is 
microscopic or macroscopic; the site of distant metastases; and the level of 
lactate dehydrogenase (LDH) in the serum (Balch et al., 2009).  Melanomas are 
staged from 0-IV, with stage 0 having no evidence of a primary tumor to stage IV, 
which is any primary tumor presenting with lymph node and distant metastases 
(Table 2 and 3).    
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Table 2: Melanoma TNM Classification 
T Classification Thickness Ulceration Status/Mitosis 
Tis N/A N/A 
T1 < 1 mm a. without ucleration and mitosis < 1/mm2 
b. with ulceration and mitosis > 1/mm2 
T2 1-2 mm a. without ulceration 
b. with ulceration 
T3 2-4 mm a. without ulceration 
b. with ulceration 
T4 > 4 mm a. without ulceration 
b. with ulceration 
N Classification # Metastatic Nodes Nodal Metastatic Mass 
No 0 nodes N/A 
N1 1 node a. micrometastases 
b. macrometastases 
N2 2-3 nodes a. micrometastases 
b. macrometastases 
c.  in-transit metastasis without lymph node involvement 
N3 4 or more metastatic lymph 
nodes or in-transit metastasis 
with lymph node involvement 
M Classification Site Serum LDH 
M0 0 sites N/A 
M1a Distant skin, subcutaneous, or 
nodal mets 
Normal 
M1b lung metastases Normal 
M1c all other visceral metastasis Elevated 
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Thanks to increased public awareness of the disease and increased 
dermatological screening, 85% of melanoma patients present at stage I or II, 
15% percent of patients have lymph node metastasis, stage III, and less than 2% 
of patients have distant metastasis, stage IV.  The five-year survival rate of 
melanoma diagnosed at stage I, where the melanoma in less than 2.00 mm thick  
and there is no lymph node or distant metastasis, is 98%. However, if the 
melanoma is diagnosed at stage IV, where the cancer has spread to parts of the 
body remote from the primary tumor, either by discontinuous metastasis to 
distant organs, tissues, or via the lymphatic system to distant lymph nodes, the 
five-year survival rate drops to just 15% (J. Jiang, Tang, & Liang, 2011; Krapcho 
et al., 2009). 
Table 3: AJCC Stage Groupings for Melanoma 
Stage Clinical Stage Grouping Pathologic Stage Grouping 
Percent Survival 
5 year 10 year 
0 Tis N0 M0 pTis N0 M0 N/A N/A 
IA T1a N0 M0 pT1a N0 M0 97% 95% 
IB T1b N0 M0 pT1b N0 M0 92% 86% 
T2a N0 M0 pT2a N0 M0 
IIA T2b N0 M0 pT2b N0 M0 81% 67% 
T3a N0 M0 pT3a N0 M0 
IIB T3b N0 M0 pT3b N0 M0 70% 57% 
T4a N0 M0 pT4a N0 M0 
IIC T4b N0 M0 pT4b N0 M0 53% 40% 
III Any T N1-3 M0 
IIIA pT1-4a N1a M0 78% 68% 
pT1-4a N2a M0 
IIIB pT1-4b N1a M0 59% 43% 
pT14-b N2a M0 
pT1-4a N1b M0 
pT1-4a N2b M0 
pT1-4a/b N2c M0 
pT1-4b N1b M0 
IIIC pT1-4b N2b M0 40% 24% 
Any T N3 M0 
IV Any T Any N M1 Any T Any N M1 15-20% 10-15% 
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D.  Melanoma Treatment 
 As mentioned above, stage I and II melanomas are treated by wide 
excision, with the amount of normal skin removed depending on the thickness of 
the melanoma.  The patient may undergo a sentinel lymph node biopsy as well.  
If the lymph node does contain cancerous cells, a lymph node dissection will also 
be done.  For more aggressive stage II and stage III patients, the above 
treatments as well as the adjuvant immunotherapy therapy of interferon-α (IFNα) 
or interleukin-2 (IL-2) is generally administered.  Immunotherapy is given to 
melanoma patients in the hopes of activating their body’s immune system so it 
will destroy any cancer cells in the body.  Some stage III patients may also 
benefit from radiation or chemotherapy.  Stage IV patients generally have both 
tumor and lymph node excisions, as well as removal of distant metastases that 
can be reached surgically.  Metastases that cause symptoms but cannot be 
reached surgically may also be treated with radiation, immunotherapy, targeted 
therapy, or chemotherapy.  Since it is often very hard to cure metastatic 
melanoma, many stage III and stage IV patients will enter a clinical trial of new 
chemotherapy drugs, new specific-target drugs, or combinations of different 
types of treatments.  The discovery of specific genetic mutations that factor in 
both the initiation and progression of the disease have allowed for the creation of 
targeted therapy that may be more specific and beneficial for the individual 
melanoma patient.  
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E.  Melanoma Epidemiology and Risk Factors 
 Melanoma is typically seen in white male patients over the age of 40.  
However, in patients under the age of 40, melanoma is more common in women.  
In men, melanomas are commonly found on the upper back or on the head and 
neck.  However, in women, melanomas generally develop on the lower legs (W. 
Y. Kim et al., 2009; Siegel, Naishadham, & Jemal, 2012).  While melanomas are 
10 times more likely to occur in Caucasians than Africa-Americans, Asian-
Americans, or Hispanics, patients with darker skin are more likely to present with 
advanced stage melanoma and it is frequently fatal for these populations (Cress 
& Holly, 1997; S.-H. Kim, Turnbull, & Guimond, 2011).   In dark-skinned people, 
the most common form of melanoma is acral melanomas commonly appear 
under the fingernails or toenails, on the palms on the hands, or on the soles of 
the hands.  While these areas of the body are the most common places for 
melanomas to develop, they can appear anywhere on the skin and even in the 
eye (uveal melanoma) or the bowel. 
Melanoma occurs through the unchecked proliferation of melanocytes.  
This can be through inheriting genetic mutations in genes involved with 
melanocyte proliferation and maintenance, such as mutations in MC1R or 
CDKN2A, or through exposure to environmental factors that cause DNA 
mutations, such as activating oncogenes like BRAF or NRAS.  The most 
common cause of melanoma is UV damage from the sun (Erler et al., 2006; 
Situm, Buljan, Bulić, & Simić, 2007) and there are numerous risk factors that can 
indicate a person’s susceptibility to the disease.  Having fair skin means that one 
	  	  	   12	  
produces less melanin to protect oneself from damaging UV radiation.  People 
with blond or red hair, blue or green eyes, and who freckle or sunburn easily are 
more likely to develop melanoma than someone with a darker complexion.  
Those who have a history of sunburn, where they have had one or more 
blistering sunburns as a child, have an increased risk of melanoma as an adult.  
Those who live closer to the equator or a higher elevation, where the sun’s rays 
are more direct, experience a higher level of UV radiation.  People with jobs who 
work outdoors are exposed to more UV radiation than those who work indoors 
and have an increased risk of melanoma.  Finally, people who naturally have 
more than 50 ordinary moles on their body have an increased risk of melanoma 
(Egeblad & Werb, 2002; Volkovova, Bilanicova, Bartonova, Letašiová, & 
Dusinska, 2012). 
 While ultraviolet radiation direct from the sun is the most common cause 
of melanoma, ultraviolet radiation exposure from indoor tanning beds has been 
linked to an increase in melanoma susceptibility.  The International Agency for 
Research on Cancer, an affiliate of the World Health Organization (WHO), 
includes ultraviolet tanning devices in its Group 1, a list of the most dangerous 
cancer-causing substances.  Group 1 also includes agents such as plutonium, 
cigarettes, and solar UV radiation (Choi, Jang, Min, & Song, 2011; Ghissassi et 
al., 2009; Shyu, Hsu, Wang, Wang, & Lin, 2007; Zhou et al., 2011).  Just one 
indoor tanning session increases users’ risk of developing melanoma by 20 
percent, and each additional session during the same year boost the risk almost 
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another two percent (Ameln, Muschter, Heimesaat, Breier, & Ben B Wielockx, 
2012; Boniol, Autier, Boyle, & Gandini, 2012). 
 
F.  Inherited Predisposition to Melanoma 
 There are also genetic mutations that increase an individuals’ chance of 
having the disease.  Some rare genes have a relative high risk of causing 
melanoma, thereby having high penetrance, while some more common genes 
have relatively low risk, or low penetrance.  One such common gene is the G-
protein-coupled receptor MC1R (melanocortin 1 receptor).  Investigations into the 
genetics of mouse coat color have shown that this gene regulates both the 
tanning response of the skin and hair and skin color in humans (Beaumont et al., 
2011; Sullivan & Graham, 2007).  MC1R variants that are associated with having 
red hair and pale skin lead to inefficient cyclic AMP (cylic adenosine 
monophospate) signaling stimulation upon UV exposure.  This leads to an 
impairment of melanin production in the skin and to a reduction in 
photoprotection (Beaumont et al., 2005; Chambers et al., 1995).  Another 
commonly mutated gene in familial melanoma is CDKN2A (cyclin-dependent 
kinase inhibitor 2A).  About 5-12% of all melanoma are estimated to be 
hereditary and about 40% of these are associated with CDKN2A mutations 
(Goldstein et al., 2006; Sullivan & Graham, 2007).  This gene, located on 
chromosome 9p21.3, encodes for two genes, p14ARF and p16INK4a. Loss of 
p14ARF results in decreased p53 activation and decreased cell apoptosis while 
loss of p16INK4A results in increased G1 to S-phase transition, or increased cell 
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proliferation.  Damaged cells lacking the ability to undergo apoptosis or stop cell 
cycle progression are likely to proliferate unchecked and form melanomas.   
Mutations that cause the skin condition xeroderma pigmentosum (XP) also 
seriously predispose one to melanoma.  Scattered throughout the genome, these 
mutations reduce a cells ability to repair DNA.  The development of melanoma 
within families carrying inherited mutations in CDKN2A or XP is highly penetrant.  
Finally, a gain-of-function mutation in the melanocyte lineage-specific 
microphthalmia transcription factor (MITF) has recently been found to predispose 
individuals to melanoma.  The variant allele was also associated with increased 
nevi and non-blue eye color (Koop et al., 1995; Yokoyama, Woods, Boyle, & 
Aoude, 2011). 
 Both environmental and genetic factors contribute to an individuals’ risk of 
developing melanoma.  By studying these factors, scientists and clinicians are 
able to better understand the disease and are able to offer better treatment 
options to patients presenting with malignant melanoma.  
 
G.  Genetics of Melanoma 
 An individuals’ cancer is made up of unique mutations and characteristics 
that have generated the malignant phenotype of cancer.  As scientists and 
physicians learn more and more about what genetic events contribute to 
melanoma, they are able to offer better treatments and therapies for the 
individual patient.  The most common mutations in malignant melanoma are 
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activating mutations of the RAS/RAF pathway and c-KIT and loss of tumor 
suppressor genes PTEN or CDKN2A (Table 4). 
 
RAS 
 The Ras sarcoma (Ras) oncoproteins are small GTPases that serve as 
signaling nodes activated in response to numerous extracellular stimuli.  
Activated Ras interacts with multiple, catalytically distinct downstream effectors 
to regulate cytoplasmic signaling networks in order to control gene expression 
and the regulation of cell proliferation, differentiation, and cell survival (Evans, 
Schrlau, Chalian, Zhang, & Koch, 2006; Wennerberg, Rossman, & Der, 2005).  
There are three Ras genes: HRAS, KRAS, and NRAS in humans.  HRAS and 
KRAS were initially discovered from two cancer-causing viruses in rats, the 
Table 4: Common Mutations in Melanoma 
Gene Mutation Function Notes 
N-RAS Point mutations 
G12V and Q61K 
Small GTPase that regulates 
cell proliferation, differentiation, 
and survival 
Most common in nodular 
melanoma 
BRAF Point mutatin at 
V600E 
Serine/threone kinase that 
regulates cell proliferation, 
differentiation, and survival 
Found in ~50% of all 
melanomas, mainly those 
arising from sun-exposed 
skin 
KIT Mutations of 
exon 11 or 13 
Transmembrane receptor 
tyrosine kinase involved in cell 
survival, prolifation, and 
differentiation 
Commonly found in 
mucousal and acral 
melanomas 
CDKN2A Point mutation, 
promoter 
methylation, 
deletion 
Encodes two tumor 
suppressors, p16INK4a and 
p14ARF which negatively 
regulated RB and p53 
pathways, respectively 
Often found in familial 
melanoma  
PTEN Epigeneric 
silencing, 
deletion 
Tumor suppressor that inhibits 
the PI3K/AKT pathway  
Found in 10-30% of 
melanoma, 5-20% of late 
stage melanomas 
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Harvey sarcoma virus and the Kirsten sarcoma virus (Bedogni et al., 2005; 
Malumbres & Barbacid, 2003), while NRAS was initially discovered in human 
neuroblastoma cancer cells (Dische, Bennett, Orchard, Stratford, & Wardman, 
1989; Hall, Marshall, Spurr, & Weiss, 1983; Lartigau et al., 1997). 
 As a G-coupled protein, Ras has an “on” and “off” state.  While in the “off” 
state, it is bound to the nucleotide guanosine diphosphate (GDP), while when the 
Ras protein is in the “on” state it is bound to the nucleotide guanosine 
triphosphate (GTP).  The exchange of GDP for GTP causes a conformational 
change that switches it to its activated form.  The process of exchanging the 
bound phosphate group is mediated by guanine nucleotide exchange factors 
(GEFs), which facilitate Ras activation, and GTPase activating proteins (GAPs), 
which facilitate Ras inactivation (Vetter & Wittinghofer, 2001). 
 Activated Ras binds to and promotes the translocation of the Raf 
serine/threonine kinase to the plasma membrane where additional 
phosphorylation events promote full Raf kinase activity.  Raf phosphorylates and 
activates the MEK1/2 dual specificity protein kinase, which in turn phosphorylates 
and activates the ERK1/2 mitogen-activated protein kinase (MAPK).  Activated 
ERK translocates to the nucleus where it phosphorylates Ets-family transcription 
factors, which in turn activate Ets-responsive promoters (Figure 2). 
 Ras is commonly mutated in 20-30% of all human cancers (Bos, 1989).  
KRAS mutations are most frequently detected in colorectal tumors, lung 
carcinomas (particularly non-small-cell lung cancer [NSCLC]), and in pancreatic 
cancers; HRAS mutations are generally associated with tumors of the head and 
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neck; and NRAS mutations are common in haematopoietic malignancies 
(Pylayeva-Gupta, Grabocka, & Bar-Sagi, 2011).  The most common mutations 
allow for the constitutive activation at the particular Ras isoform.  The glycine to 
A.  
B. 	  	  
Figure 2. RAS Pathway.  A. The exchange of GDP for GTP causes a 
conformational change in RAS that switches it to its activated form.  The process 
of exchanging the bound phosphate group is mediated by guanine nucleotide 
exchange factors (GEFs), which facilitate Ras activation, and GTPase activating 
proteins (GAPs), which facilitate Ras inactivation. B.  Activated RAS promotes the 
phosphorylation of RAF, with in turn activate MEK, which activates ERK.  This 
pathway is involved in the regulation of many cellular functions, including growth, 
proliferation, and survival. 
	  	  	   18	  
valine mutation at residue 12 (G12V) renders the GTPase domain of Ras 
insensitive to inactivation by GAP and thus stuck in its “on” state.  The glutamine 
to lysine mutation at residue 61 (Q61K) impairs GTP hydrolysis, again sticking 
Ras in its “on” state (Scheffzek, Ahmadian, Kabsch, & Wiesmüller, 1997).   
 The most commonly mutated RAS isoform in melanoma is NRAS.  
Approximately 15-20% of melanoma cases harbor point mutations, generally 
occurring at codons 12 or 61.  Activating NRAS mutations are generally 
correlated with nodular lesions, sun exposure, higher melanoma thickness, and a 
higher mitotic rate (Ellerhorst et al., 2011).  However, NRAS mutations are rarely 
found in dysplastic nevi, the most common precursor to melanoma (Albino et al., 
1989).  HRAS mutations are found in 30% of Spitz nevi, these are benign 
melanocytic lesions that occur most frequently in the first 2 decades of life 
(Bastian, LeBoit, & Pinkel, 2000).  Transgenic studies in mice have shown that 
activated HRAS mutations in melanocytes can lead to aberrant proliferation and 
transformation, especially in cooperation with inactivating mutations in tumor 
suppressors such as Cdkn2a or Trp53 (Powell et al., 1995).   
 Pharmacological inhibition of NRAS is challenging because its GTPase 
activity has so far precluded the successful design of specific small-molecule 
antagonists.  Small interfering RNA (siRNA)-mediated depletion of NRAS in 
melanoma cell lines inhibits proliferation and makes cells much more sensitive to 
chemotherapy (Eskandarpour et al., 2005).  Farnesyltransferase inhibitors (FTIs) 
block farnesylation, a key post-translational modification necessary for RAS 
activation (Sebti, 2005; Yao et al., 2005), and were hoped to inhibit NRAS.  An 
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FTI, Tipifarnib, or R115777, was evaluated in a single-agent, single-arm Phase II 
trial in patients with metastatic melanoma, but the lack of response among the 
first 14 patients led to the early closure of the trial (Gajewski et al., 2012).  Since 
it is so difficult to directly target NRAS activation, more studies are being done to 
investigate the inhibition of RAS effector pathways. 
 
RAF 
Directly downstream of Ras, Raf is commonly mutated in multiple cancers, 
including malignant melanoma, colorectal cancer, thyroid, and ovarian cancers.  
There are three isoforms of Raf, A-Raf, B-Raf, and C-Raf.  While mutations in 
either A-Raf or C-Raf are rare in cancer, the valine to glutamic acid mutation of 
B-Raf at residue 600 is the most common Raf-activating mutation, accounting for 
~90% of the B-Raf mutations that are seen in human cancers (Wellbrock, 
Karasarides, & Marais, 2004).  This mutation is thought to disrupt the interaction 
between the glycine-rich loop and the activation segment of the B-Raf kinase 
domain, freeing the activation segment and allowing the kinase to fold into the 
active confirmation. 
BRAF is most highly expressed in neuronal tissues and melanocytes as 
well as in testis and haematopoietic cells and at this time MEK is its only known 
substrate.  Activating mutations in BRAF have been identified in approximately 
50% of all melanomas, with the vast majority found in melanomas that arise from 
intermittently sun-exposed skin.  The high frequency of BRAF mutation in 
melanoma may be related to key pathways in melanocyte biology.  In response 
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to UVB radiation, α-MSH (α-melanocyte stimulating-hormone) and 
proopiomelanocortin-derived peptides bind to MCR1, which upregulate cyclic-
AMP.  This increase in cAMP leads to increased proliferation and melanogenesis 
(Halaban, 2000) through the upregulation of BRAF and subsequently ERK 
(Buscà et al., 2000).  That a principle melanocyte-specific signaling pathway 
controlling proliferation and differentiation operates through the activation of 
BRAF suggests a possible explanation for the high frequency of BRAF mutations 
in melanoma relative to other cancer types (Davies et al., 2002). 
There have been positive clinical results from phase I, II, and III trials that 
show that vemurafenib (PLX4032), a potent and selective BRAFV600E inhibitor, 
caused complete or partial tumor regression in 80% of patients carrying 
BRAFV600E tumors as well as an increased progression-free survival rate 
(Chapman et al., 2011; Flaherty et al., 2010).  Unfortunately, after an initial period 
of response to vemurafenib, most patients relapse and develop resistance to the 
drug (Flaherty et al., 2010).  Identification of the mechanisms leading to BRAF 
resistance have led to new clinical trials combining inhibitors of BRAF with MEK 
and AKT inhibitors in patients with metastatic melanoma as well as other tumor 
types harboring the BRAFV600E mutation (Curti & Urba, 2012).  Murine models of 
vemurafenib-resistant tumors have even shown that some tumors acquire a 
dependency on the drug, where removal of vemurafenib treatment results in 
tumor regression (Thakur et al., 2013).  Increased understanding of how 
melanomas become resistant to this treatment will enable better options for 
patients with these tumors. 
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KIT 
 Although BRAF mutation melanomas represent the largest genetic 
subtype of melanoma, c-Kit mutations are more common in mucosal and acral 
melanomas and they are also present in melanomas that originate in chronic 
sun-damaged skin (Beadling et al., 2008).  KIT encodes a type III 
transmembrane receptor tyrosine kinase.  Binding of KIT’s ligand, stem cell factor 
(SCF), to the extracellular domain causes the dimerization of the KIT receptor 
resulting in the autophosphorylation of its intracellular tyrosine kinase domains.  
Once activated, the tyrosine kinase domains initiate signaling in a variety of 
downstream pathways including MAPK/MEK, phosphatidylinositol 3-OH kinase 
(PI3K)/AKT, JAK/signal transducers and activators of transcription (STAT) 
pathways. 
 Many of the KIT mutations found in melanomas affect exon 11, which 
codes for the juxtamembrane domain.  This membrane is involved in 
autoinhibition of the receptor when it is not bound with its ligand, when it is 
mutated, this inhibitory function is prevented and ligand independent receptor 
dimerization and activation is enhanced (Curtin, Busam, Pinkel, & Bastian, 2006).  
Phase II clinical trails have found that patients with mutations in either exon 11 or 
exon 13 of KIT respond well to treatment with imatinib (Carvajal et al., 2011).  
Currently, patients with mucosal or acral melanomas harboring these activating 
KIT mutations are encouraged to enroll in Phase II or Phase III clinical trials 
assessing the benefits of imatinib. 
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CDKN2A 
 The CDKN2A locus encodes for two distinct tumor-suppressing proteins, 
p16INK4A and p14ARF.  p16INK4A (inhibitor of cyclin-dependent kinase) inhibits 
CDK4/6-cylin D-mediated phosphorylation and inactivation of retinoblastoma 
(RB).  In the absences of p16INK4A inhibition, CDK4/6-cylcin D phosphorylates RB, 
resulting in the release of E2F.  E2F then activates genes that are necessary for 
a cell to transition from G1 to S phase (Serrano, Hannon, & Beach, 1993).  
p14ARF (alternative reading frame) inhibits MDM2-mediated ubiquitylation and 
subsequent degradation of p53 (Kamijo et al., 1998; Pomerantz et al., 1998; Stott 
et al., 1998; Y. Zhang, Xiong, & Yarbrough, 1998), thereby inhibiting activation of 
the p53 apoptotic pathway (Figure 3).  The two products p16INK4A and p14ARF 
negatively regulate RB and p53 pathways respectively, and their loss 
predisposes to the development of melanoma. 
 CDKN2A mutations are commonly found in individuals with familial 
melanoma and melanoma-prone families (Hussussian, Struewing, & Goldstein, 
1994; Kamb et al., 1994).  These families are diagnosed with familial atypical 
multiple mole melanoma (FAMMM), an autosomal dominant disease 
characterized by multiple, melanocytic nevi, usually more than 50, and a family 
history of melanoma.  Interestingly, BRAFV600E induces p16INK4A expression and 
senescence in primary human melanocytes in vitro (Gray-Schopfer et al., 2006; 
Michaloglou et al., 2005).  p16INK4A upregulation contributes to the induction of 
senescence in nevi and p16INK4A defects are found in dysplastic, but not benign, 
nevi.  These studies indicate the p16INK4A may act as a stop mechanism to  
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BRAF-induced melanocyte transformation.  However, with further mutations that 
lead to the silencing of p16INK4A, the OIS is overcome and the melanoma 
progression continues. 
 In the situation of CDKN2A loss, drugs that inhibit CDK4/6 have been 
suggested as potential therapeutics.  Multiple in vitro studies combining CDK4/6 
inhibitors with MEK inhibitors or BRAF inhibitors have shown increased 
melanoma cell apoptosis (J. Li, Xu, Yang, Li, & Dong, 2010).  However, a Phase 
II clinical trial of flavopiridol, a pan CDK inhibitor, showed no significant clinical 
activity in malignant melanoma (Burdette-Radoux et al., 2004).  More clinical 
Figure	  3.	  	  CDKN2A	  Locus	  and	  Pathway.	  	  CDKN2A	  codes	  for	  two	  distinct	  tumor	  suppressors,	  p16INK4a	  and	  p14ARF	  that	  share	  two	  common	  exons	  (exons	  2	  and	  3)	  but	  have	  separate	  first	  exons,	  p16INK4a	  has	  1α	  and	  p14ARF	  has	  1β.	  	  P16INK4a	  inhibits	  cell	  cycle	  progression	  by	  inhibiting	  CDK4/6	  inhibition	  of	  Rb.	  	  p14ARF	  inhibits	  apoptosis	  and	  cell	  cycle	  arrest	  by	  inhibiting	  MDM2	  inhibition	  of	  p53.	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Phase I and II trials are being done looking novel and more specific CDK4/6 
inhibitors in combination with other chemotherapies or specific targeting drugs. 
 
PTEN 
 Loss of the lipid phosphataste PTEN (phosphate and tensin homologue) is 
detected in 10-30% of cutaneous melanomas and is also seen in 5-20% of late 
stage melanomas (Wu, Goel, & Haluska, 2003).  PTEN dephosphorylates the 3’ 
position of phosphatidylinositol-(3,4)-P2 (PIP2) and phosphatidylinositorl-(3,4,5)-
P3 (PIP3).  This directly antagonizes the activity of PI3K, which phosphorylates 
PIP2 and PIP3 resulting in their activation of AKT, a serine/threonine kinase that 
normally exists in the cytoplasm in an inactive conformation.  Upon activation of 
PI3K, AKT is recruited to the cell membrane and phosphorylated at 2 critical 
residues (Thr308 and Ser473) and activates its downstream targets, including 
mTOR (Figure 4).  AKT activity has been shown to regulate many cellular 
processes, including metabolism, growth/size, survival, motility, invasion, and 
angiogenesis (D DD Sarbassov, Ali, & Sabatini, 2005; Restuccia & Hemmings, 
2010; Yecies & Manning, 2011).  Therefore, PTEN loss in melanoma results in 
activated AKT and an increase in the many cellular processes it regulates. 
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 PTEN gene mutations and deletions are mutually exclusive with activating 
NRAS mutations in melanoma.  In contrast, many melanomas with loss of PTEN 
have concurrent BRAF activating mutations (Tsao, Goel, Wu, Yang, & Haluska, 
2004).  In melanoma, NRAS and BRAF mutations are mutually exclusive.  
Activation of NRAS induces PI3K activity.  However, BRAF and PTEN are not 
	  
Figure 4. PTEN Pathway. PTEN dephosphorylates the 3’ position of 
phosphatidylinositol-(3,4)-P2 (PIP2) and phosphatidylinositorl-(3,4,5)-P3 
(PIP3).  This directly antagonizes the activity of PI3K, which phosphorylates 
PIP2 and PIP3 resulting in their activation of AKT, a serine/threonine kinase 
that normally exists in the cytoplasm in an inactive conformation.  Upon 
activation of PI3K, AKT is recruited to the cell membrane and phosphorylated 
at 2 critical residues (Thr308 and Ser473) and activates its downstream 
targets, including mTOR.  AKT activity has been shown to regulate many 
cellular processes, including metabolism, growth/size, survival, motility, 
invasion, and angiogenesis	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mutually activating so the pathways cooperate to stimulate proliferation.  Indeed, 
genetically engineered mouse models (GEMMs) have shown that loss of PTEN 
is required for the transformation of melanocytic lesions to invasive melanomas 
in the setting of activated BRAFV600E (Dankort, Curley, Cartlidge, & Nelson, 
2009).   
  There have been numerous scientific and clinical studies on the use of 
PI3K-AKT and its pathway inhibitors in melanoma.  An example is the use of the 
mTORC1 inhibitor Rapamycin.  Use of this drug inhibits signaling downstream of 
mTORC1, but also results in feedback activation of PI3K, resulting in 
hyperactivation of AKT(Tabernero et al., 2008).  This compensatory activation of 
AKT may be the reason behind the lack of clinical activity of single-agent 
treatment with rapamycin in several cancers, including melanoma (Margolin et 
al., 2005).  Future studies and clinical trials using PI3K/AKT pathway inhibitors 
alone and in tandem with other therapeutics will be necessary to better 
understand how to treat metastatic melanoma patients with PTEN loss. 
 
H.  Genetically Engineered Mouse Models of Melanoma 	   Genetically engineered mouse models of melanoma have been used to 
phenocopy the human disease and allow us to better understand the initiation 
and progression of melanoma in vivo.  By manipulating the expression of 
different genes, such as the ones mentioned above, believed to be involved in 
melanoma, scientists can better understand not only affects of the gene itself but 
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also how that gene affects the entire system of the mouse, from tumor 
microenvironment to immune system.   
 The earliest mouse models were used in the early 1900’s when 
melanocytic tumors arose spontaneously in inbred mouse strains.  These 
spontaneous melanomas, including the well-known B16 cell line, were 
transplanted to congenic mice and could also be cultured, studied, and 
manipulated in vitro (Damsky & Bosenberg, 2010).  As technology improved, 
methods of manipulating gene expression, such as the CRE-lox P system, have 
been developed to allow scientists to control when and where the genes are 
expressed or deleted.  These systems of in vivo genetic manipulation have 
allowed great insight into the initiation and progression of melanoma. 
 The most popular system to generate conditional mouse models is the 
CRE-Lox P system (Agar & Young, 2005; Argos et al., 1986; Davies et al., 2002; 
Haass & Herlyn, 2005; Krapcho et al., 2009; Maldonado et al., 2003; Sauer & 
Henderson, 1988; Sternberg, Sauer, Hoess, & Abremski, 1986).  This system 
allows for site-directed recombination of target sequences to regulate or 
manipulate gene expression.  In this system, Cre (cyclization recombination) is a 
site-specific DNA recombinase that recognizes a specific 34-bp site, known as 
lox P (locus of X-over P1) sites.  When two lox P sites flank a region of DNA, the 
Cre enzyme will excise all DNA sequences located between the two sites.  
Mouse models generally make use of this technology by placing lox P sites on 
either side of an exon to create a null allele or on either side of a stop codon to 
generate constitutive expression. 
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 In order to generate mouse models of melanoma, scientists have taken 
advantage of the melanocyte-specific expression of the tyrosinase family of 
genes:  tyrosinase (Tyr); tyrosinase related protein 1 (TRP1); and dopachrom 
tautomerase (DCT) to drive expression of their genes of interests only in those 
cells (Ball et al., 1994; Bansal & Nikiforov, 2010; Forbes et al., 2008; Jafari et al., 
1995; Mintz & Klein-Szanto, 1992; Slipicevic & Herlyn, 2012).  By combining 
melanocyte specific expression with the Cre-lox P system, many models of 
melanoma have been developed to increase our understanding of the disease 
and the genes involved in its initiation and progression, some of which are 
described below (Table 5). 
* References cited in text 
Table 5:  Genetically Engineered Mouse Models of Melanoma 
Genetic Modification Background Spontaneous 
Melanoma 
Metastasis 
Tyr::SV40T-antigen 25-100% at 47.5 
weeks 
Yes 
Tyr::HRasV12G Ink4a/Arf -/- 60% at 6 months No 
Tyr::HRasV12G Ink4a -/- ~50% by 75 weeks No 
Tyr::HRasV12G Arf -/- ~50% by 40 weeks No 
Tyr::NRasQ61K Ink4a/Arf -/- 94% at 6 months Metastasis to the lymph 
nodes, lung, and liver 
Tyr::CreERT2/ 
LSLKRasG12D/p53L/L 
45% at 31 weeks No 
Tyr::CreERT2/ 
LSLKrasG12D/p16L/L 
73% at 24 weeks No 
Tyr::CreERT2/ 
LSLKrasG12D/p53L/L/p16L/L 
100% at 9 weeks No 
Tyr::CreERT2/ 
LSLKrasG12D/p53L/L/Lkb1L/L 
100% at 11 weeks Metastasis to lymph nodes, 
lung, liver, and spleen 
Tyr::CreERT2/     BraV600E/
PtenL/L 
100% at 10 weeks Metastasis to lymph nodes 
and lung 
Tyr::CreERT2/BRafV600E/ 
PtenL/L/Bcat-STA 
100% at 6 weeks Metastasis to lymph nodes 
and lung 
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 One of the first models of melanoma had melanocyte-specific expression 
of the SV40 (Simian Vacuolating Virus 40) large T antigen that disrupts both the 
Rb and p53 pathways (Mintz & Klein-Szanto, 1992).  These mice developed 
spontaneous and UV-induced melanomas that metastasized.  In this model, the 
majority of the melanomas were ocular melanomas as opposed to the more 
commonly seen cutaneous melanomas. 
 Multiple models were generated to examine the role of CDKN2A in 
melanoma.  Models utilized either complete loss of p16Ink4a and p19Arf, or loss of 
either tumor suppressor, combined with Tyr::HRasV12G, a constitutively 
activated HRas transgene on a melanocyte specific promoter.  Mice with loss of 
both p16Ink4a and p19Arf developed cutaneous melanomas that were highly 
vascularized, locally invasive, amelanotic, and nodular (Chin, Pomerantz, Polsky, 
& Jacobson, 1997).   Mice that had loss of either p16Ink4a or p19Arf developed 
spontaneous melanomas at 75 and 40 weeks respectively.  Mice with 
homozygous loss of p16Ink4a demonstrated loss of p19Arf expression and mice 
with homozygous p19Arf loss demonstrated loss of p16Ink4a expression.  These 
results suggest the p16Ink4a and p19Arf work together to hinder melanoma 
progression in vivo (Sharpless, Kannan, Xu, Bosenberg, & Chin, 2003).  Finally, 
loss of p16Ink4a and p14Arf was combined with melanocyte-specific activated NRas 
(Tyr::NRasQ61K).  As mentioned previously, NRas is the most common isoform 
of Ras mutated in human melanoma, while HRas and KRas are rarely mutated.  
These mice developed highly pigmented and invasive cutaneous melanoma.  
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These tumors were also able to metastasize to the lymph nodes, lung, and liver 
(Ackermann et al., 2005).  
 The development of the conditional TyrCreERT2 allele allowed for the 
possibility of mouse melanoma models with controlled spatial expression of a 
gene of interest (Balch et al., 2009).  This allele is under the control of a 
tamoxifen-inducible system, so that only when tamoxifen is administered to the 
mouse will the Cre-lox P recombination occur in melanocytes.  Conditional 
activation of KRasG12D with somatic loss of both p16Ink4a and p53 has been 
shown to cooperate in melanoma formation (Monahan et al., 2010) and adding 
Lkb1 loss to this model generates metastatic disease. (Liu et al., 2012)  In 
another model, the conditional activation of BrafV600E with somatic loss of Pten 
induces metastatic melanoma (Dankort et al., 2009) and adding stabilized β-
catenin to this model increases distant metastases (Damsky et al., 2011). 
 Genetic mouse models of melanoma have generated much knowledge as 
to the genes involved in the initiation and progression of the disease.  These 
models help scientists to understand how these genetic events not only affect the 
melanoma, but also the tumor microenvironment and immune system.   
 
I.  Melanoma and Metastasis 
 While the majority of patients are diagnosed with stage I or II melanoma, 
17% of patients are diagnosed with stage III or IV melanoma, meaning that they 
have metastases to lymph nodes (stage III) or distant organs (stage IV).  
Melanoma metastasis causes the majority of morbidity and mortality associated 
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with the disease (Balch, Soong, et al., 2001b).  The one-year survival rates in 
melanoma patients with clinically apparent metastasis to one, two or three 
different visceral sites is 36%, 13%, and 1%, respectively (Damsky, Rosenbaum, 
& Bosenberg, 2010).  Even “new” melanomas may metastasize as metastasis 
can occur early in melanoma progression, even from a thin primary tumor 
(Bedrosian et al., 2000).  Though treatment options have improved for patients 
with metastatic disease, it is an important area of research to find new targets for 
treatment as patients often relapse and those that are thought to be cured of the 
disease can sometimes discover new metastases many years after the “curative” 
treatment (Balch, Soong, et al., 2001b).   
Once melanoma cells switch from RGP to VGP the tumor has obtained 
invasive potential and is more likely to metastasize.  These malignant cells grow 
deeper into the dermis and have access to lymphatic or blood vasculature that 
can aid in the dissemination of the cells.  Melanoma cells also undergo genetic 
changes that can aid in its progression to metastasis, such as the decrease in E-
cadherin expression.  Decreasing E-cadherin frees the cells from linkages with 
adjacent keratinocytes and allows the cell to become more motile (Haass & 
Herlyn, 2005).   
Primary melanomas generally first metastasize to regional lymph nodes 
(Meier et al., 2002).  It is known that melanoma cells can secrete VEGF-C 
(Saharinen, Tammela, Karkkainen, & Alitalo, 2004), which induces 
lymphangiogenesis, and high levels of VEGF-C are related to deep lymph node 
involvement with the tumor (Vihinen et al., 2007).  Melanoma cells also secrete 
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increased levels of matrix metalloproteinases (MMPs) that help to degrade the 
extracellular matrix (ECM) surrounding the tumors thereby allowing the 
melanoma cells to move more freely (Seftor et al., 2001).  By creating new lymph 
vessels, the now-motile malignant cells are able to intravasate into the lymphatic 
system and spread to regional lymph nodes.  Patients diagnosed with melanoma 
exceeding 1mm in depth generally receive sentinel lymph node dissection in 
order to prohibit the spread of the disease. 
The most common sites of distant metastasis are skin, lung, brain, liver, 
bone, and intestine (Damsky et al., 2010).  How a cancer cell is able to 
extravasate and seed sites of distant metastasis is an increasingly popular field 
of research.  Multiples studies looking at protein expression in human melanoma 
samples by immunohistochemistry (IHC) have found that the expression of 
specific genes correlates with melanoma metastasis to specific sites.  Melanoma 
cells express chemokine receptors, including CXCR4, which could possibly aid in 
the honing of the cells to sites of distant metastasis.  CXCR4 expression has also 
been linked to poor prognosis and increases distant metastasis in patients with 
malignant melanoma (Scala et al., 2005).  The expression of different integrins 
can also predict sites of metastasis.  Melanomas that express integrin αvβ3 are 
more likely to develop lung metastases (Hieken, Ronan, Farolan, Shilkaitis, & 
Gupta, 1999), while melanomas expressing αvβ1 develop lymph node metastasis 
(Hieken, Ronan, Farolan, Shilkaitis, & Gupta, 1996).  Finally, expression of the 
p75 NGF (nerve growth factor) receptor in melanoma correlates with brain 
metastasis (Marchetti, Murry, Galjour, & Wilke-Greiter, 2003).  These findings 
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suggest the melanoma cells in the process of metastasis can develop multiple 
genetic changes that confer advantages in seeding new sites of distant 
metastasis. 
Melanoma is known to be more aggressive than other cancers.  The most 
common mutation in melanoma is activation of the Ras/Raf pathway.  Introducing 
Ras into normal melanocytes results in melanomas that are significantly more 
metastatic than introducing Ras into normal fibroblasts or epithelial cells (P. B. P. 
Gupta et al., 2005).  These findings show that the intrinsic features of 
melanocytes, or at least their response to RAS transformation, may be 
responsible for their quick metastasis.  This may be a reflection of the fact that 
melanocytes are derived from neural crest cells.  These cells are characterized 
by their expression of motility-associated genes, such as Slug, ERBB3, CD44, 
and Nodal (Siegel et al., 2012), that can not only mediate the neural crest cell 
motility, but also tumor migration.  Understanding the mechanisms that allow 
melanoma to spread to both lymph nodes and other sites of distant metastasis 
will allow for the discovery of therapies and screens to better treat patients with 
advanced disease. 
 
J.  Summary 
 Here we have discussed the development and progression of melanoma.  
There are many factors that contribute to an individuals’ risk of the disease, from 
environmental risk factors, like exposure to UV radiation, to the hereditary 
acquisition of mutations, such as the CDKN2A mutation commonly found in 
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familial melanoma patients.  Melanomas may also contain many different genetic 
mutations that drive their development.  Activation mutations in oncogenes, such 
as NRAS, BRAF, and c-KIT, and loss of tumor suppressor genes, such as 
p16INK4A, p14ARF, or PTEN, are seen in multiple types of melanomas.  By 
studying how these mutations and genes interplay in in vitro melanoma cell lines 
and in vivo melanoma mouse models, scientists and clinicians will be able to 
discover therapies and therapeutics that will ultimately give the individual 
melanoma patient the best possible treatment. 
Chapter	  II	  	   Hypoxia-­‐Inducible	  Factors	  	  
The availability of oxygen in the cellular environment has many effects on 
multiple cellular functions.  Oxygen is necessary for cellular respiration, the 
metabolic reaction within cells that converts biochemical energy from nutrients 
into ATP (adenosine triphosphate) which the cell then uses to perform a myriad 
of functions, including: biosynthesis of amino acids, fatty acids, and other natural 
products; locomotion; and the transport of molecules across cell membranes.  If 
the amount of oxygen in the cellular environment is limited, then the cells must 
switch to an anaerobic pathway of respiration and must also regulate multiple 
pathways in order to maximize the use of its resources.  The genes involved in 
the ability of a cell to “sense” the availability of oxygen in the environment have 
been of interest to both basic scientists as well as translational medicine.   
 
A.  Structure of Hypoxia-Inducible Factors 
 The hypoxia-inducible factor (HIF) is a heterodimeric transcription factor 
composed of a labile α-subunit and a stable β-subunit that are members of the 
PAS family (PER, ARNT, and SIM family).  There are three alpha subunits in the 
human genome, HIF1α, HIF2α, and HIF3α, and three HIFβ genes, also known 
as ARNT (aryl hydrocarbon receptor nuclear translocator) (Semenza, 2001).  The 
HIFα/β dimer binds to a core DNA motif (G/ACGTG) in hypoxia response 
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elements (HRE) that are associated with a broad range of transcriptional targets 
(Semenza et al., 1996).   
 Both HIFα and HIFβ have basic helix-loop-helix (bHLH) domain at their N-
terminus for dimerization and DNA binding.  Following the bHLH domain are two  
 
 
PAS domains, PER (period circadian protein), Arnt, and Sim (single-minded 
protein) PAS-A and PAS-B.   PAS domains frequently mediate protein-protein 
interactions and are often regulated by the binding of their partner to their 
hydrophobic core.  One or both of the HIFα PAS domains have been functionally 
	  
	  
Figure 5.  Domain structure of HIF. Both HIFα and HIFβ have basic helix-
loop-helix (bHLH) domain at their N-terminus for dimerization and DNA 
binding.  Following the bHLH domain are two PAS domains. PAS domains 
frequently mediate protein-protein interactions and are often regulated by the 
binding of their partner to their hydprophobic core. The HIFα-subunits contain 
two oxygen-dependent degradation domains located in the central region of 
the protein: the amino-terminal oxidation-dependent degradation domain 
(NODDD) and the carboxy-terminal oxygen-dependent degradation domain 
(CODDD),.  There are also two transactivation domains on the 1 and 2α-
subunits, the amino-terminal activation domain (NTAD) and a carboxy-
terminal activation domain (CTAD), but only the NTAD on HIF3α. 
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implicated in nuclear localization, HIF stabilization via heat shock protein 90 
(HSP90) association, and binding with cofactors for target gene specificity, but 
the most important function is their heterodimerization of the α-subunit with 
ARNT (J. J. Yang et al., 2005).  The HIFα-subunits contain two oxygen-
dependent degradation domains located in the central region of the protein: the 
amino-terminal oxidation-dependent degradation domain (NODDD) and the 
carboxy-terminal oxygen-dependent degradation domain (CODDD),.  There are 
also two transactivation domains on the α-subunits, the amino-terminal activation 
domain (NTAD) and a carboxy-terminal activation domain (CTAD) that 
associates with the CH-1 (cysteine/histidine rich) domain on HIF’s transcriptional 
co-activator p300 (Figure 5) (Schofield & Ratcliffe, 2004).  
 
B.  Regulation of Hypoxia-Inducible Factors 
HIF is a major regulator of the cellular response to the availability of 
oxygen in the cellular environment, but it also regulates many of the genes 
involved in the adaptation of cancer cells to the hypoxic microenvironment 
created by a tumor as it outgrows its blood supply.  When oxygen is freely 
available in the cellular environment, HIFα is hydroxylated at specific proline 
residues, Pro402 and Pro564, by an oxygen-dependent prolyl hydroxylase 
(PHD).  There are three PHD isoforms, PHD1, PHD2, and PHD3.  PHD 2 has 
been shown to generally target HIF1α while PHD1 and PHD3 generally target 
HIF2α (Fong & Takeda, 2008). The hydroxylation of the α-subunit allows the 
alpha subunit to be recognized by its E3 ubiquitin ligase, the von-Hippel Lindau 
	  	  	   38	  
(VHL) tumor suppressor protein, pVHL.  pVHL polyubiquinates HIFα within its 
oxygen-dependent domain (ODD), thereby targeting HIFα for proteosomal 
degradation (Ivan et al., 2001; Jaakkola et al., 2001).  In times of hypoxia, where 
there is little or no oxygen available in the cellular environment, or in the setting  
 
 
 
is 
Figure 6. Post-translational Regulation of HIF. When oxygen is freely 
available in the cellular environment, HIFα is hydorxylated at specific proline 
residues, Pro402 and Pro564, by an oxygen-depenent prolyl hydroxylase 
(PHD). The hydroxylation of the α-subunit allows the alpha subunit to be 
recognized by its E3 ubiquitin ligase, the von-Hippel Lindau (VHL) tumor 
suppressor protein, pVHL.  pVHL polyubiquinates HIFα within its oxygen-
dependent domain (ODD), thereby targeting HIFα for proteosomal 
degradation.  Both HIF1α and HIF2α are also regulated by the hydroxylation 
of an asparaginyl residue, thereby disrupting association with p300 in 
normoxic conditions.  In times of hypoxia, where there is little or no oxygen 
available in the cellular environment, or in the setting of pVHL loss, HIFα is no 
longer degraded and can translocate into the nucleus, bind with its β-subunit 
and regulate its target genes.	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of pVHL loss, HIFα is no longer degraded and can translocate into the nucleus, 
bind with its β-subunit and regulate its target genes (Figure 6).  Over 60 direct 
HIF target genes have been identified, including many implicated in the 
pathogenesis of melanoma: VEGF, PDGFβ, IL-8, alphaVbeta3 integrin, and N-
Cadherin (Semenza, 2003).  
Both HIF1α and HIF2α are also regulated by the hydroxylation of a 
specific asparaginyl residue located at the N-terminus, Asn803 and Asn851 
respectively (Lando, Peet, Whelan, Gorman, & Whitelaw, 2002).  This 
hydroxylation is catalyzed by factor inhibiting HIF (FIH) and asparginyl 
hydroxylation causes the disruption of the association of the α-subunit with the 
CH-1 domain of the p300 co-activator (Figure 6) (Mahon, Hirota, & Semenza, 
2001).    
 
C.  Function of HIF 
 The most commonly studied of the alpha subunits are HIF1α and HIF2α.  
There is little known about HIF3α, though it lacks the c-terminal transactivation 
domain (CTAD) found on HIF1α and HIF2α and thus cannot bind with p300.  
HIF3α has multiple splice variants that can interact with HIF1α, HIF2α, and HIFβ.  
It may act as a negative regulator of hypoxia-inducible gene expression as it 
competes for HIFβ binding with HIF1α and HIF2α (Heikkilä, Pasanen, Kivirikko, & 
Myllyharju, 2011).  While HIF1α and HIF2α share many of the same target 
genes, they are not wholly redundant in function.  HIF1α -/- mice have lethality at 
embryonic day 11, mainly due to cardiovascular malformation and neural tube 
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defects (Iyer et al., 1998).  HIF2α -/- mice have lethality between embryonic days 
9.5 and 13.5 with divergent phenotypes depending on the background of the 
mice – including lung maturation defects and catecholamine deficiency 
(Compernolle et al., 2002; Tian, Hammer, Matsumoto, Russell, & McKnight, 
1998).  HIF1α is expressed ubiquitously while HIF2α expression is tissue 
specific, occurring in endothelial cells, type II pneumocytes, cardiomyocytes, 
fibroblasts of the kidney, interstitial cells of the pancreas and duodenum, and in 
hepatocytes (Ema et al., 1997; Flamme, Fröhlich, Reutern, & Kappel, 1997; Tian, 
Figure 7.  Targets of HIF1α and HIF2α. HIF1α and HIF2α produce 
overlapping yet distinct gene expression profiles, with HIF1α uniquely 
targeting the genes involved in glycolysis and HIF2α uniquely targeting genes 
such as Oct4, CyclinD1, TWIST1, TGFα, and EPO. 
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McKnight, & Russell, 1997).  Finally, HIF1α and HIF2α produce overlapping yet 
distinct gene expression profiles, with HIF1α uniquely targeting the genes 
involved in glycolysis and HIF2α uniquely targeting genes such as Oct4, 
CyclinD1, TWIST1, TGFα, and EPO (Figure 7) (Keith, Johnson, & Simon, 2012).  
D.  HIF In Cancer 
 The majority of human cancers and their metastases have been shown to 
have increased levels of HIF1α or HIF2α (or both) protein (relative to surrounding 
normal tissue) (Zhong, De Marzo, Laughner, Lim, & Hilton, 1999) (Table 4).  
Clinical data has shown an association between HIF1α and / or HIF2α protein 
levels with increased human mortality in many cancers.  In addition to this 
correlative data from the clinic, there is a large body of experimental data 
showing that HIFα loss of function results in decreased tumor growth, 
vascularization, and metastasis, whereas HIFα gain of function has the opposite 
effect (Semenza, 2010). 
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Adapted from Giaccia (2008) and Semenza (2010)  
 When HIF is activated, it regulates numerous genes that might actually 
help the cancerous cells adjust to the harsh microenvironment of the tumor.  HIF 
activates genes involved in angiogenesis, such as VEGF (vascular endothelial 
growth factor), PDGFβ (platelet derived growth factor β), IL-8 (interleukin-8), and 
OCT-4 (octamer-binding transcription factor 4), allowing for the increased 
delivery of oxygen and nutrients to the quickly growing tumor (Hickey & Simon, 
2006).  HIF also activates genes that can breakdown the extracellular matrix, 
such as MMPs (matrix metalloproteinase).  This allows the tumor to grow and 
metastasize.  HIF regulates genes that are involved in the epithelial to 
mesenchymal transition (EMT), such as N-Cadherin and TWIST, thought to be 
Table 6: HIF Activation in Human Cancer 
Tumor Type HIF1! HIF2! HIF! and Poor Prognosis 
Astrocytoma + ND HIF1! 
Bladder + + HIF1! 
Breast + + HIF1! 
Colorectal + + HIF1! and HIF2! 
Cervical + ND HIF1! 
Endometrial + ND HIF1! 
Esophageal, SCC + ND HIF1! 
Gastric + ND HIF1! 
Glial + + HIF1! 
Head and Neck + + HIF1! and HIF2! 
Hepatocellular + + HIF2! 
Laryngeal + ND HIF1! 
Lung NSCLC + + HIF2! 
Melanoma + + HIF2! 
Nasopharyngeal + + HIF1! 
Osteosarcoma + + HIF1! 
Ovarian + + HIF1! and HIF2! 
Pancreatic + + HIF1! 
Prostate + + HIF2! 
Renal + + HIF1! 
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one of the hallmarks of metastasis (Esteban et al., 2006; Imai et al., 2003).  It is 
apparent that having high levels of HIF1α or HIF2α, or both, allows for the 
selection of aggressive cancer cells. 
 
E.  HIF in Renal Cell Carcinoma 
 The majority of the studies on HIF have been done in the setting of renal 
cell carcinoma (RCC).  Von Hippel-Lindau disease is a rare, autosomal dominant 
genetic condition where one copy of the VHL gene has a mutation and produces 
a faulty VHL protein (pVHL) but the second copy still produces a functional 
protein.  Once the second copy of the gene is mutated, individuals with this 
disease develop a spectrum of benign and malignant, tumors, including tumors in 
the central nervous system, retinal hemangioblastomas, pheochromocytomas, 
pancreatic neuroendocrine tumors, pancreatic cysts, endolymphatic sac tumors, 
epididymal papillary cystadenomas, and clear cell renal cell carcinomas (ccRCC) 
(Kaelin, 2008).  Deletion of chromosome 3-25-26 resulting in the loss of VHL is 
common in sporadic ccRCC (Baldewijns et al., 2010).  With the inactivation of 
VHL, HIFα is no longer be targeted for proteosomal degradation, even if there is 
plenty of oxygen.  Indeed, high levels of HIF1α and, more frequently HIF2α, are 
often observed in RCC. Scientists and clinicians have taken advantage of these 
elevated levels of HIF expression advantage of elevated HIFα expression to 
better understand the role of HIF in cancer development and progression and to 
develop targeted therapies for the disease. 
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 Both HIF1α and HIF2α have been shown to play a role in the tumor 
initiation or progression, or both, in RCC.  Data from both VHL defective RCC cell 
lines and primary tumors from RCC patients show that disregulation of HIF1α 
and HIF2α play a role in renal carcinogenesis.  HIF2α expression in VHL-/- pre-
neoplastic renal lesions correlates with increased dysplasia (Mandriota et al., 
2002).  VHL -/- RCC cell lines produce both HIF1α and HIF2α, and sometimes 
just HIF2α, in normoxic conditions (Maxwell et al., 1999).  In vivo expression of 
HIF2α is sufficient to suppress VHL -/- tumor growth and tumor suppression by 
pVHL can be overcome with HIF2α expression but not HIF1α (Volkovova et al., 
2012).  These data suggest that HIF2α is more oncogenic than HIF1α in RCC. 
 Many targets of both HIF1α and HIF2α are involved in renal cell 
carcinogenesis.  RCC is noted to be highly vascular, and many HIFα targets 
involved in angiogenesis are upregulated in this disease, including VEGF, PDGF 
(platelet derived growth factor), PLGF (placental growth factor), and COX-2 
(cyclooxygenase-2).  Indeed, the expression level of VEGF In RCC is known to 
strongly correlate with microvessel density, a measure of the degree of 
angiogenesis (Kluger et al., 2008).  Other HIFα targets include genes that are 
involved in the glycolytic pathway of glucose metabolism (GLUT1 [glucose 
transporter 1), cell proliferation and survival (TGFα [transforming growth factor 
α), and metastasis (MMPs) (Banumathy & Cairns, 2010).  By activating glucose 
metabolism, the cancerous cells are able to continue growing and proliferating in 
the absence of oxygen – a phenomenon known as the Warburg Effect commonly 
seen in most solid tumors (Warburg, 1925; Warburg, Negelein, & Posener, 
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1924).  Reduced levels of mitochondrial DNA and respiratory chain proteins as 
well as increased levels of glycolytic enzymes, hallmarks of the Warburg Effect, 
have been reported in RCC (Baldewijns et al., 2010).  
While traditional treatment of RCC has involved the use of IFNα and 
interleukin-2 (W. Y. Kim & Kaelin, 2006), scientists and clinicians have taken 
advantage of the oncogenic nature of HIFα in the disease and have targeted its 
upstream and downstream pathways in patients with the disease (figure 8).  
While it would be ideal to be able to target HIFα itself, blocking the activity of 
transcription factors with small molecules is very difficult in a clinical setting.  The 
mTOR inhibitor, temsirolimus, has been shown to significantly improve both 
progression-free survival and overall survival in patients with metastatic RCC and 
poor prognostic features (Hudes et al., 2007).  This drug has become a first-line 
standard of care for these patients.  Multi-targeteted receptor tyrosine kinases 
(RTK) inhibitors, such as Sunitinib (targeting VEGFR-2 PDGFR, FMS-like 
tyrosine kinase 3 [FLT-3], and c-KIT) and Sorafenib (which targets BRAF, CRAF, 
VEGFR-2, VEGFR-3, PDGFR, FLT-3, and c-KIT) have also been found to 
significantly improve progression-free survival in clinical trials of patients with 
metastatic ccRCC.  Both drugs have been FDA-approved to treat advanced RCC 
(Escudier, Eisen, et al., 2007a; Motzer et al., 2007; Rock et al., 2007).  Finally, 
treatment with bevacizumab, a monoclonal antibody against VEGF, in 
combination with IFNα, also resulted in significantly improvement in progression-
free survival compared with treatment with IFNα alone (Coon et al., 2010; 
Escudier, Pluzanska, et al., 2007b).   
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 With increased knowledge of the biology of RCC, the treatment of patients 
with these tumors has significantly improved.  By targeting the pathways involved 
in the initiation and progression of the tumor, notably, the pathways both 
upstream and downstream of HIFα, scientists and clinicians have been able to 
improve the survival of these patients.  There are ongoing clinical trials to find 
new and better treatments, and drugs involved in targeting the HIF-mediated 
pathways are sure to be in the mix. 
	  	  
	  
Figure 8.  Targeting the HIF Pathway in RCC.   Multiple stages in the HIF 
pathway are targeted with therapies in RCC. The mTOR inhibitor, 
temsirolimus, has been shown to significantly improve both progression-free 
survival and overall survival in patients with metastatic RCC and poor 
prognostic features. Multi-targeteted receptor tyrosine kinases (RTK) 
inhibitors, such as Sunitinib and Sorafenib, have also been found to 
significantly improve progression-free survival in clinical trials of patients with 
metastatic ccRCC. Finally, treatment with bevacizumab in combination with 
IFNα resulted in significantly improvement in progression-free survival 
compared with treatment with IFNα alone.  
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F.  HIF and Metastasis   
 While HIF has been shown to play an oncogenic role in RCC, in many 
cancers elevated levels of either HIF1α or HIF2α, or both, is associated with 
disease progression and metastasis (table 4).  Metastasis occurs in solid cancers 
when the disease spreads from the original tissue or organ of occurrence to 
	  
	  
Figure 9.  Steps to Metastasis.  A tumor cell undergoes a series of steps to 
metastasize. First, tumor cells undergo a change of phenotype that allows 
them to become dedifferentiated, more motile, and more invasive through 
EMT.  Tumor cells then breakdown and invade into the extracellular matrix to 
eventually penetrate the blood or lymphatic vessel walls (intravasation) to 
become circulating tumor cells (CTC). CTCs must then go through 
extravasation and adapt to the microenvironment of a secondary organ, often 
undergoing mesechymal to epithelial transition in order for metastasis to 
occur.  These extravating cells can either immediately start growing a new site 
of metastasis or lie dormant for many years before beginning to proliferate.   
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another, non-adjacent tissue or organ. This process is generally thought to 
consist of a series of rate-limiting steps (figure 9) (G. P. Gupta & Massagué, 
2006).  First, tumor cells undergo a change of phenotype that allows them to 
become dedifferentiated, more motile, and more invasive through EMT.  Tumor 
cells then breakdown and invade into the extracellular matrix to eventually 
penetrate the blood or lymphatic vessel walls (intravasation) to become 
circulating tumor cell\s (CTC).  In order for metastasis to occur, CTCs must then 
go through extravasation and adapt to the microenvironment of a secondary 
organ, often undergoing mesenchymal to epithelial transition (MET) (Lu & Kang, 
2010).  Many studies have shown that hypoxia and HIF play an active role in 
each of these steps. 
Epithelial to Mesenchymal Transition 
 EMT is characterized by a loss of cell adhesion, downregulation of E-
cadherin (a cell-cell adhesion molecule) expression, and increased cell motility 
(Thiery, 2002).  Epithelial tissues line the cavities and surfaces of structures 
throughout the body.  These cells are highly differentiated and have a singular 
purpose in maintaining homeostasis in their environment.  Mesenchymal tissue is 
undifferentiated and may still develop into other connective tissues in the body.  
Mesenchymal cells are able to migrate, unlike epithelial cells, which lack mobility 
(Thiery, 2002).   
 Hypoxia has been found to induce EMT by HIF-dependent upregulation of 
transcriptional repressors of E-cadherin, such as SLUG, SIP1, SNAIL, TWIST1, 
TCF3, ZEB1, and ZEB2 (Lu & Kang, 2010).  Induction of EMT in multiple cell 
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lines, including cells from ovarian, renal, colorectal, breast, lung, and head and 
neck squamous cell cancers (HNSCC), by hypoxia or stabilized HIF expression 
has been demonstrated by showing a shift from epithelial to mesenchymal 
markers and an increase in migration and invasion ability (J. Jiang et al., 2011).  
A mouse model of lung cancer with stabilized HIF2α found increased levels of 
mRNA transcripts associated with EMT, including SIP1, SNAIL, ZEB1 and 
vimentin (W. Y. Kim et al., 2009).  These studies demonstrate that hypoxia and 
HIF play an important role in EMT. 
Breakdown of the Extracellular Matrix 
 The extracellular matrix (ECM) provides structural support to cells, 
separates tissues from one another, and helps to regulate intercellular 
communication.  Components of the ECM are produced intracellularly by resident 
cells and then secreted by exocytosis.  There are many components of the ECM, 
including fibrous proteins and glycosaminoglycans (GAGs).  GAGs are 
carbohydrate polymers that attract water, keeping the ECM and its cells 
hydrated.  Fibers, including collagen, elastin, fibronectin, and laminin, give 
structural support to cells while allowing them to have elasticity and movement.  
By coordinating the composition of the ECM, cells are able to maintain a 
structurally sound microenvironment (S.-H. Kim et al., 2011). 
 Hypoxia has been shown to upregulate the expression of lysyl oxidase 
(LOX) in a HIF1α-dependent manner in human breast and head and neck tumors 
(Erler et al., 2006).  LOX is an extracellular enzyme that covalently modifies 
collagens to increase focal adhesion kinase activity, cell migration, and 
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metastasis.  Orthotopic tumors grown in nude mice from cancer cell lines with 
reduced LOX expression had significantly fewer lung metastases in comparison 
with wild-type tumors.  Matrix metalloproteinases (MMPs) are able to degrade 
numerous extracellular matrix proteins and have been shown to be upregulated 
in multiple cancers and this increase correlates with advanced tumor stage, 
increased invasion and metastasis, and shortened survival (Egeblad & Werb, 
2002).  Hypoxia and HIF1α have been shown to regulate the expression of 
MMP2 and MMP9 in lung, gastric, and breast cancer cells (Choi et al., 2011; 
Shyu et al., 2007; Zhou et al., 2011), and have been implicated in the regulation 
of MT1-MMP (MMP14) (Ameln et al., 2012).  By regulating the enzymes involved 
in the breakdown of the ECM, HIF expression enables cancer cells to 
breakthrough the basement membrane and invade into the ECM. 
Intravasation and extravasation 
 Intravasation occurs when cancer cells breach the basal membrane and 
gain access to the blood and lymphatic vessels to become CTCs.  Hypoxic 
upregulation of VEGF, a known target of HIF, results in increased angiogenesis 
and lymphangiogenesis, facilitating tumor dissemination by providing additional 
routes of escape from the primary tumor.  High levels of VEGF are also 
associated with increased microvascular permeability and interstitial fluid 
pressure (IFP) in breast, lung, and gastrointestinal tumors, both of which 
contribute to an increased chance of intravasation (Sullivan & Graham, 2007).  
The increased motility of the tumor cells and the increased production of MMPs 
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(described above) allows the cells to move to and invade into the newly made 
tumor vascular system.  
 The CTCs move out of the blood and lymphatic vessels to a secondary 
site through a process known as extravasation.  The neovasculature in a tumor is 
generally poorly structured and more permeable than the normal tissue 
vasculature.  The tumor cells must be able to survive in circulation and then 
breakthrough the normal tissue to the secondary site.  Studies have shown that 
the time between intravasation and extravasation for tumor cells is potentially 
quite short, where extravasation follows intravasation in as little as 1-3 hours 
(Chambers et al., 1995).  It is possible that the hypoxic induction of VEGF 
persists long enough to aid in extravasation.  Exposing tumor cells to hypoxia in 
vitro before intravenous inoculation into mice increased VEGF expression and 
enhanced their metastatic potential and invasive ability (Sullivan & Graham, 
2007).  One explanation could be that the hypoxia induction of VEGF through 
HIF facilitates the movement of tumor cell into the blood and lymphatic vessels 
and also from these vessels out to a secondary site for metastasis.   
Colonization of Secondary Organs 
 A majority of cells that extravasate remain solitary and dormant.  The 
tumor cells that are able to migrate to the vicinity of a pre-existing blood vessel 
are generally the only ones that are able to resume proliferation (Koop et al., 
1995).  Some extravasating cells with begin to proliferate very quickly, other cells 
will become dormant and wait many years before they begin to proliferate.   Like 
the primary tumor, these sites of metastasis will also develop hypoxia.  By 
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activating the same pathways that helped the primary tumor overcome its 
hypoxic microenvironment, the tumor cells will be able to grow and proliferate in 
the new site.  HIF and its targets, like the ones described above, greatly facilitate 
the adaptation of the tumor cells in metastatic lesions. 
 Hypoxia and the induction of HIF are critical steps driving the selection of 
the metastatic phenotype at all stages of metastasis.  From EMT to colonizing 
the secondary site, HIF activation allows the tumor cells to adapt to the harsh 
microenvironment of the primary tumor site, become motile, invade into the ECM 
and break through the walls of the blood and lymphatic vessels to colonize 
distant sites of metastases.  Understanding how HIF and its upstream regulators 
and downstream targets aid tumor cells may help to uncover new targets for the 
treatment of metastatic disease. 
 
G.  HIF and Melanoma 
 One of the distinguishing characteristics of the epidermis is the absence of 
vasculature that results in a constitutive low level of tissue oxygenation.  While 
the dermis is well oxygenated and vascularized (with pO2 of around 10%), the 
pO2 gradient of the epidermis can range from mildly hypoxic (5% O2) to severely 
hypoxia (0.5% O2) (Evans et al., 2006).  This setting of hypoxia allows for the 
activation of HIFα in normal settings and can aid in the progression of melanoma.  
Indeed, recent data has shown that melanocytes reside in a hypoxic environment 
and that this hypoxia, in a HIF-dependent manner, cooperates with activation of 
Akt to transform melanocytes (Bedogni et al., 2005).    
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 Several lines of evidence indicate that hypoxia and HIF signaling play an 
important role in melanomagenesis.  Melanomas are hypervascular tumors that 
are resistant to radiation therapy, yet responsive to immunomodulatory agents 
such as IL-2 and INFα.  This response to therapies is very similar to RCC, in 
which HIF is known to play an important role.  Second, primary melanomas and 
their metastases have been documented to be hypoxic by either direct pO2 
measurements or by pimonidazole staining (a marker of intercellular hypoxia) 
(Dische et al., 1989; Lartigau et al., 1997).  Third, HIF1α and HIF2α are 
overexpressed in melanomas and HIF2α predicts poor clinical outcome 
(Ghissassi et al., 2009; Giatromanolaki et al., 2003).  Finally, there is much 
experimental data connecting HIF expression and regulation with melanoma. 
 On a molecular level, HIF activation is a consequence of several of the 
signature genetic events found in melanoma and described in Chapter 1 (figure 
10).  Loss of function mutations of PTEN result in an Akt-mediated increase of 
mTOR activity leading to the increased translation of HIFα (Boniol et al., 2012; 
Sodhi, Montaner, Miyazaki, & Gutkind, 2001). HIF is upregulated by mutated 
RAS and BRAF as well (Beaumont et al., 2011; Blancher, Moore, Robertson, & 
Harris, 2001; Kumar et al., 2007; Sodhi et al., 2001) and is required for the 
growth of Ras-induced fibrosarcomas in nude mice.  Tumors lacking HIF1α in 
these mice were smaller than wild-type controls (Beaumont et al., 2005; Ryan et 
al., 2000).  Recent reports shows that HIF expression is required for the survival 
of BRAFV600E cell lines when grown under hypoxic conditions (Goldstein et al., 
2006; Kumar et al., 2007).  Importantly, the effects of HIF activation in melanoma 
	  	  	   54	  
can be further augmented by hypoxia as demonstrated by increases in HIF 
protein levels, enhanced transcriptional activation of its target genes, and 
functional consequences, such as synergistic transformation of melanocytes by 
constitutive active Akt and hypoxia / HIF (Bedogni et al., 2005; Blancher et al., 
2001; Yokoyama et al., 2011). 
 
 
 It is apparent that hypoxia and HIF play an important role in melanoma.  
By studying how HIF is regulated in melanoma and the effects that this regulation 
has on the disease, scientists and clinicians may better understand the disease.  
	  
	  
Figure 10.  HIF Activation in Melanoma Pathways.  An increase in HIF 
expression is a result of many of the pathways disregulated in melanoma.  The 
RAS/RAF pathway has been shown to increase HIF expression through ERK and 
the PI3K/AKT pathway has been shown to increase HIF translation though 
mTOR.  
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Increased knowledge of the pathways involved in both the initiation and the 
progression of melanoma will allow for better treatments for patients with 
advanced malignant melanoma. 
Chapter	  III	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A.  OVERVIEW 
Malignant melanoma is characterized by a propensity for early lymphatic 
and hematogenous spread.  The hypoxia-inducible factor (HIF) family of 
transcription factors are upregulated in melanoma by key oncogenic drivers and 
transactivate genes involved in cancer initiation, progression, and metastases.  
Here, we show that Hif1α or Hif2α inactivation abrogates metastasis in a Pten-
deficient, Braf-mutant genetically engineered mouse model of melanoma without 
affecting primary tumor formation. HIF1α and HIF2α drive melanoma invasion 
and invadopodia formation and mediate these effects by activation of SRC, 
through PDGFRα and FAK respectively, and by coordinating ECM degradation 
via MT1-MMP and MMP2 expression.  These results establish the importance of 
HIFs in melanoma progression and demonstrate that HIF1α and HIF2α activate 
independent transcriptional programs that promote metastasis by coordinately 
regulating cell invasion and ECM remodeling. 
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B.  INTRODUCTION 
  
Melanoma is one of the most lethal forms of skin cancer and is increasing 
in incidence (Siegel, Ward, Brawley, & Jemal, 2011; Wennerberg et al., 2005). 
Early-stage melanomas are highly curable by surgical resection and adjuvant 
therapy is rarely necessary.  However later stage melanomas that have 
progressed to metastasis have a much lower chance of long-term survival 
(Flaherty, Hodi, & Fisher, 2012; Malumbres & Barbacid, 2003).   
HIF is a heterodimeric transcription factor composed of an alpha and a 
beta subunit.  There are three alpha subunit genes: HIF1α, HIF2α, and HIF3α, 
which partner with a beta subunit HIFβ (also known as the arylhydrocarbon 
nuclear translocator, ARNT) to form a transcriptionally active complex. HIFα 
subunits are post-translationally hydroxylated on conserved prolyl residues in an 
oxygen-dependent manner and then degraded by the von Hippel-Lindau (pVHL) 
E3 ubiquitin ligase complex, while HIFβ subunits are constitutively stable.  
Therefore, HIFα subunits are stabilized under hypoxia but degraded under 
conditions of normoxia (Hall et al., 1983; Kaelin & Ratcliffe, 2008; W. Y. Kim & 
Kaelin, 2004).   
HIF regulates genes that would be predicted to be protumorigenic, 
including genes involved in adaptation to an unfavorable tumor 
microenvironment.  For example, HIF activates proangiogenic genes, such as the 
vascular endothelial growth factor A (VEGFA), platelet derived growth factor B 
(PDGFB), and IL-8, genes that regulate cellular pH, such as carbonic anhydrase 
9 (CA9), and genes that regulate glycolytic cellular metabolism, such as lactate 
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dehydrogenase A (LDHA) and phosphofructokinase (PFK) (W. Y. Kim & Kaelin, 
2004; Semenza, 2003; Vetter & Wittinghofer, 2001). While the majority of 
transcriptional targets of HIF1α and HIF2α are overlapping, it is now clear that 
HIF1α and HIF2α have unique target genes as well.  For example HIF1α 
specifically regulates multiple genes involved in glycolysis, while HIF2α specific 
targets include OCT4 and cyclin D1 (CCND1) amongst others (Bos, 1989; Hu, 
Wang, Chodosh, Keith, & Simon, 2003; Keith et al., 2012; W. Y. W. Kim et al., 
2006; Raval et al., 2005).  
Hypoxia has been shown to enhance the invasiveness and metastatic 
capacity of tumor cells and is critical for placental development, a process which 
requires invasion of the maternal decidua by trophoblast cells (Adelman, 
Gertsenstein, Nagy, Simon, & Maltepe, 2000; Dahl, Robertson, Weaver, & 
Simon, 2005; Kozak, Abbott, & Hankinson, 1997; Pylayeva-Gupta et al., 2011; 
Vaupel, 2008). HIF activation plays a key role in these processes through 
transcriptional regulation of genes involved in breakdown of the extracellular 
matrix (ECM): such as matrix metalloproteases (MMPs); genes that are involved 
in the epithelial to mesenchymal transition (EMT): E-Cadherin (CDH1) and N-
Cadherin (CDH2); genes that promote metastases: TWIST1 and lysyl oxidase 
(LOX); as well as genes implicated in motility, adhesion, and invasion such as 
MET/HGF, CXCR4/SDF-1, and alphaV (ITGAV) beta3 (ITGB3) integrin (Dahl et 
al., 2005; W. Y. Kim & Kaelin, 2004; Scheffzek et al., 1997; Semenza, 2003).  
Both HIF1α and HIF2α have been shown to be overexpressed in 
melanoma (Ellerhorst et al., 2011; Giatromanolaki et al., 2003).  The dermal-
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epidermal junction where melanocytes reside is relatively hypoxic and HIF1α is 
necessary for the AKT-mediated transformation of melanocytes (Albino et al., 
1989; Bedogni et al., 2005). HIF activation is a consequence of several of the 
signature genetic events found in melanoma. For example, HIF is upregulated by 
mutated Ras and BRaf as well as loss of function mutations of PTEN (Bastian et 
al., 2000; Blancher et al., 2001; Harris, 2002; Kumar et al., 2007; Sodhi et al., 
2001). In addition, HIF appears to mediate a prosurvival signaling pathway 
downstream of the micropthalmia transcription factor (MITF) (Buscà et al., 2005; 
Powell et al., 1995), but has also been reported to downregulate MITF 
expression, suggesting a possible negative feedback loop (Cheli et al., 2012; 
Eskandarpour et al., 2005; Feige et al., 2011).  Based on these observations, we 
sought to directly explore the contributions of HIFs to melanoma pathogenesis in 
a relevant in vivo context. To this end, we studied the impact of inactivation of 
Hif1α or Hif2α in the context of an autochthonous, genetically engineered mouse 
(GEM) model of melanoma as well as in vitro on cellular invasion, motility, and 
stiffness. 
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C.  RESULTS 
Inactivation of Hif1α or Hif2α does not affect the initiation or progression of Braf-
activated, Pten-deficient melanomas.    
 For this study we utilized a previously characterized conditional mouse 
model of melanoma based on melanocyte-specific Pten-inactivation and Braf 
V600E-activation (hereafter called Pten; Braf) (Dankort et al., 2009; Sebti, 2005; 
Yao et al., 2005).  In this model, temporal and spatial expression of Cre 
recombinase is controlled by tamoxifen and the tyrosinase promoter respectively.  
Genetic recombination of floxed alleles therefore occurs in tyrosinase-positive 
cells exposed to 4-hydroxytamoxifen (4-OHT) giving rise to melanomas that are 
highly metastatic to regional lymph nodes (Dankort et al., 2009; Gajewski et al., 
2012).   
To determine whether Hif1α or Hif2α play an active role in melanoma 
initiation and progression we intercrossed Pten; Braf mice with mice harboring 
conditional knock-out alleles of Hif1α and Hif2α (hereafter called Hif1 L/L and 
Hif2L/L respectively) to generate cohorts of 1) Pten; Braf; Hif1L/L, 2) Pten; Braf; 
Hif2L/L and 3) Pten; Braf control mice.  At 6 weeks of age, mice from the above 
cohorts were treated with topical 4-OHT at the base of the tail to induce 
recombination of the floxed alleles and initiate tumorigenesis.  Pigmented 
lesions, limited to the site of 4-OHT application, began to appear approximately 
three weeks later (Supplemental Figure 1A).  Upon tumor formation, validation of 
Hif1α or Hif2α loss was confirmed by western blot of tumor lysates 
(Supplemental Figure 1B). However, neither inactivation of Hif1α or Hif2α 
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appeared to affect melanoma pigmentation grossly (Figure 11A), their growth 
rate relative to control Pten; Braf tumors (Supplemental Figure 11C), or the 
percent of mice living [mice were sacrificed secondary to primary tumor burden] 
(Figure 11B). Moreover, inactivation of Hif1α or Hif2α in Pten-null, Braf-activated 
melanomas did not appear to alter the tumor-free survival of the mice harboring 
these tumors (Supplemental Figure 1D) nor the weight of the tumor itself 
(Supplemental Figure 1E). In aggregate, these data suggest that Hif1α and Hif2α 
are dispensable for the initiation and progression of Pten-null, Braf-activated 
melanomas. 
Histological analysis confirmed that inactivation of Hif1α or Hif2α in Pten; 
Braf melanomas did not appreciably alter their pigmentation and that the tumors 
were virtually indistinguishable (Figure 11A).  The melanomas continued to have 
a dense stroma and reside at the epidermal-dermal junction consistent with 
previous observations (Dankort et al., 2009; Wellbrock et al., 2004). Constitutive 
expression of Hif1α and Hif2α (due to inactivation of pVHL) is intimately 
associated with the pathogenesis of renal cell carcinoma and in this context as 
well as other solid tumors, Hif1α and Hif2α activation potently stimulates 
angiogenesis (Halaban, 2000; W. Y. Kim et al., 2009; W. Y. Kim & Kaelin, 2004).  
We therefore also examined the effects of Hif1α or Hif2α inactivation on the 
vascularity of Pten; Braf melanomas. Loss of Hif1α or Hif2α decreased 
melanoma vascularity (as assessed by the number of CD31+ microvessels per 
high powered field) of Pten; Braf; Hif1L/L and Pten; Braf; Hif2L/L melanomas 
relative to Pten; Braf controls (Supplemental Figure 1F and 1G).  Thus, while 
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Hif1α and Hif2α regulate melanoma angiogenesis, this did not impact melanoma 
growth.   
 
HIF1α and HIF2α expression are increased in melanoma metastases and their 
inactivation abrogates lymph node metastases of Pten; Braf melanomas.    
Both expression of HIF as well as tumor hypoxia correlate with an 
increased rate of metastases in many tumor types (Buscà et al., 2000; Harris, 
2002; Vaupel, 2008).  We therefore hypothesized that while Hif1α and Hif2α did 
not play prominent roles in melanoma initiation or progression they might impact 
its metastatic capacity.   
To explore this possibility, tissue microarrays (TMAs) spotted with nevi, 
thin (Breslow thickness of invasion ≤ 2mm) and thick primary melanomas, and 
melanoma metastases were stained with antibodies specific to HIF1α and HIF2α 
and scored in a blinded fashion (Figure 11C and 11D). HIF1α had a relatively 
consistent increase in expression from nevus to metastasis.  HIF2α expression, 
however, was more variable with an increase in its expression seen in the 
metastases compared to thin, primary melanomas. 
Examination of the regional lymph nodes in Pten; Braf mice revealed 
significant areas of pigmentation (Figure 11E, gross) as previously described in 
this model (Dankort et al., 2009; Davies et al., 2002).  In contrast, the 
locoregional lymph nodes from mice harboring Pten; Braf; Hif1L/L and Pten; Braf; 
Hif2L/L melanomas had either significantly fewer foci or completely lacked visible 
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pigmentation suggesting that deletion of Hif1α or Hif2α may abrogate lymph 
node metastases.   
Histologic examination of the lymph nodes from mice harboring Pten; Braf 
melanomas confirmed the presence of clusters of melanin pigment-positive 
melanoma cells in the subcapsular sinuses of lymph nodes indicative of 
melanoma metastases (Figure 11E, 10X and 20X).  However, examination of 
lymph nodes from Pten; Braf; Hif1L/L and Pten; Braf; Hif2L/L mice showed a 
relative absence of these melanotic foci.  Quantification of lymph node 
metastases revealed that mice with Pten; Braf melanomas have a significantly 
higher percentage of lymph node metastases than mice harboring Pten; Braf; 
Hif1L/L and Pten; Braf; Hif2L/L melanomas (Figure 11F) as well as a higher 
percentage of melanin per lymph node (Supplemental Figure 1H).  Detailed 
histologic assessment confirmed that HIF deficiency did not simply result in loss 
of pigmentation in the metastasis nor result in a different pattern of metastatic 
spread. Therefore, Hif1α and Hif2α are required for lymphatic metastases in 
Pten, Braf melanomas. 
 
Hypoxia enhances melanoma cell invasion and invadopodia formation.   
Previous work has shown that melanoma cell lines expressing mutant 
BRAFV600E express detectable levels of HIF1α under normoxia (Chapman et al., 
2011; Flaherty et al., 2010; Kumar et al., 2007).  We wished to examine HIF1α or 
HIF2α expression in human melanoma cells in comparison to human neonatal 
foreskin melanocytes under conditions of normoxia or hypoxia.  To this end, a 
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panel of BRAFV600E mutant melanoma cell lines or melanocytes was cultured in 
normoxia (21% O2) or hypoxia (1% O2) overnight.  Whole cell extracts were then 
immunoblotted for HIF1α or HIF2α (Figure 12A).  Most melanoma cell lines 
displayed variable levels of both HIF1α and HIF2α in hypoxia.  While there were 
detectable levels of HIF1α in cells cultured under normoxia (Supplemental Figure 
2), they were significantly lower than those found in hypoxia and we did not see 
appreciable levels of normoxic HIF2α.    
Hypoxia reportedly increases the invasiveness of cancer cells and 
trophoblast stem cells (TS cells) in certain physiologic contexts in vitro. This 
hypoxia-induced invasion is reduced by deletion of ARNT or co-inactivation of 
Hif1α and Hif2α (Dahl et al., 2005; Flaherty et al., 2010).  However, whether 
inactivation of HIF1α or HIF2α alone was sufficient to decrease invasion was not 
examined.  We first wanted to confirm that hypoxia could induce the invasion of 
melanoma cells through matrigel.  To this end, A375 SM and WM2664 cells were 
allowed to invade a matrigel chamber under both normoxia and hypoxia. Hypoxia 
significantly increased the number of cells invading the matrigel chamber in both 
cell lines (Figure 12B and 12C) and also appeared to increase melanoma cell 
motility (Supplemental Figure 3A and 3B) in an in vitro wound closure assay.  
Therefore, consistent with previously published results in other tumor types, 
hypoxia increases cell motility and invasion of melanoma cells.  
Invadopodia are dynamic, actin-rich protrusions of the cellular membrane 
that are points of both extracellular matrix (ECM) degradation as well as 
attachment (Curti & Urba, 2012; Murphy & Courtneidge, 2011).  Invadopodia 
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coordinate ECM degradation with cell motility and correlate highly with cancer 
cell invasiveness.  Given this relationship between invadopodia and tumor cell 
invasion, we examined whether hypoxia could induce invadopodia formation in 
melanoma cell lines.  A375 SM and WM2664 cells were plated on Alexa Fluor 
568 labeled fibronectin (artificial ECM) and allowed to form invadopodia in either 
normoxia or hypoxia overnight.  Melanoma cells cultured under hypoxia had 
significantly more cells with active invadopodia (defined as co-localization of F-
actin [phalloidin staining] and cortactin punctae, and degradation of fibronectin) 
as well as a higher number of invadopodia per cell (Figure 12D [invadopodia are 
highlighted with yellow arrowheads], 12E, and 12F). In aggregate, these data 
suggest that hypoxia promotes melanoma invasiveness as well as the formation 
of active invadopodia.   
 
Hypoxia-induced invasion and invadopodia formation are dependent upon HIF1α 
or HIF2α.  
We next asked whether either HIF1α or HIF2α were necessary for 
hypoxia-induced invasion and invadopodia formation of melanoma cell lines.  
siRNAs directed to HIF1α and HIF2α were effective and specific at knocking-
down HIF1α and HIF2α in A375 SM and WM2664 cells cultured in hypoxia 
(Figure 13A). While HIF1α or HIF2α knockdown did not appreciably affect cell 
proliferation or survival, they both affected multiple parameters of cell motility and 
invasion relative to cells expressing non-specific siRNAs.  These included 
decreases in cellular migration under hypoxia (Supplemental Figure 3C and 3D) 
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but not normoxia (Supplemental Figure 3E, and 3F), matrigel invasion (Figure 
3B, 3C and Supplemental Figure 4A, 4B), and invadopodia formation (Figure 3D, 
3E, and Supplemental Figure 4C).  Therefore, the increased invasiveness and 
numbers of invadopodia induced by hypoxia are both HIF1α and HIF2α 
dependent.  Finally, to assess the functional relevance of these in vitro 
outcomes, we stably silenced HIF1α or HIF2α and assessed these cells ability to 
form tumors upon tail vein injection.  shRNA to HIF1α or HIF2α significantly 
decreased the number of lung metastases after tail vein injection of A375 SM 
cells (Figure 13F and 13G). Therefore, the in vitro decrease in motility, invasion, 
and invadopodia formation induced by silencing of HIF1α or HIF2α are reflected 
in in vivo metastatic tumor formation. 
 
HIF1α and HIF2α upregulate PDGFRα and FAK and are necessary for hypoxia-
induced SFK activation. 
Invadopodia were first described in chicken fibroblasts and were notably 
increased in fibroblasts transformed with v-SRC (Murphy & Courtneidge, 2011; 
Thakur et al., 2013). It is now clear that SRC activation is a critical step in 
invadopodia formation.  While various physiologic and pathogenic stimuli have 
been shown to upregulate SRC activity, only a few reports have examined 
whether hypoxia can result in SRC activation (Beadling et al., 2008; Yeatman, 
2004).  We confirmed that SRC family kinases (SFK) could be activated by 
hypoxia by immunoblotting A375 SM and WM2664 cells with an antibody that 
recognizes phosphorylated Tyr416 within the activation loop of c-SRC or its 
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equivalent site on the other SFK members (Lyn, Fyn, Lck, Yes and Hck) [Figure 
14A].  In keeping with the notion that hypoxia-induced phosphorylation of 
SFKTyr416 is dependent upon HIF1α or HIF2α, knock-down of HIF1α or HIF2α 
under hypoxia or deletion of Hif1α or Hif2α in Pten; Braf melanomas significantly 
decreased levels of SFKTyr416 (Figure 14B and 14C). Importantly, silencing of 
HIF1α or HIF2α did not appear to alter total SRC protein levels, suggesting that 
HIF1α and HIF2α RNAi were not merely decreasing total SRC expression, but 
were specifically regulating SRC activity (Figure 14B and 14C).     
Since HIF1α and HIF2α are transcription factors, we predicted that SFK 
activation is mediated through one or more of their transcriptional targets.  In this 
regard, TWIST1, a well characterized HIF target gene, was recently shown to 
promote invadopodia formation and metastases via a PDGFRα dependent 
upregulation of SFK in breast cancer cells (Curtin et al., 2006; Eckert et al., 2011; 
Gort et al., 2008; M.-H. Yang et al., 2008).  We therefore asked whether HIF1α 
and/or HIF2α regulate TWIST1 or PDGFRα in melanoma cells.  We found that 
siRNA of HIF1α (but not HIF2α) specifically downregulated PDGFRA mRNA and 
protein levels under hypoxia in melanoma cell lines (Figure 14B and 14D) and 
that inactivation of Hif1α (but not Hif2α) decreased Pdgfra mRNA expression in 
primary tumors (Supplemental Figure 5A).  Unexpectedly, TWIST1 expression 
was unaffected (Supplemental Figure 5C and 5D).   
Since our data indicate that HIF2α regulates pSFK, through a pathway 
distinct from the HIF1α-PDGFRα axis, we examined whether HIF2α regulates 
expression of focal adhesion kinase (FAK), an activator of SRC (Carvajal et al., 
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2011; Yeatman, 2004). Correspondingly, siRNA of HIF2α (but not HIF1α) under 
hypoxia specifically downregulated both FAK mRNA and protein levels (Figure 
14B and 14E) and Fak mRNA expression was decreased in Pten; Braf 
melanomas with Hif2 inactivation (Supplemental Figure 5B).  Moreover, 
chromatin immunoprecipitation (ChIP) with antibodies specific to HIF1α and 
HIF2α demonstrated that both HIF1α and HIF2α were recruited to the promoter 
regions of PDGFRA and FAK in a hypoxia-dependent manner (Supplemental 
Figure 5E, 5F, 5G, and 5H). While at first approximation this would seem 
contrary to the results showing that HIF1α and HIF2α specifically regulate 
PDGFRα and FAK. However, these results are in keeping with previous studies 
that have shown that recruitment of transcriptional coactivators rather than 
promoter occupancy, determines HIF target gene specificity (Hu, Sataur, Wang, 
Chen, & Simon, 2007; Serrano et al., 1993).   
Finally, concurrent knock-down of HIF1α and HIF2α in the same cell 
resulted in an additive decrease of pSFK (Figure 4F) as well as matrigel invasion 
(Figure 14G, 14H, and 14I).  In aggregate, these data show that hypoxia 
activates SRC in a manner dependent upon both HIF1α and HIF2α, which act 
via parallel yet distinct signaling programs involving PDGFRα and FAK, 
respectively.  
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Expression of stabilized HIF1α or HIF2α is sufficient to enhance normoxic 
melanoma cell invasion, invadopodia, and reduce cell stiffness.  
 While the above data suggest that HIF1α and HIF2α are necessary for 
hypoxia dependent activation of SFK, invadopodia formation, and invasion, we 
wanted to determine whether HIF1α and HIF2α were sufficient to mediate these 
cellular signaling events and phenotypes.  To this end we generated A375 SM 
and WM2664 cells expressing stabilized versions of HIF1α and HIF2α (HIF1dPA 
and HIF2dPA) that remain stable under normoxia (Kamijo et al., 1998; Kondo, 
Klco, Nakamura, Lechpammer, & Kaelin, 2002; Pomerantz et al., 1998; Stott et 
al., 1998; Y. Zhang et al., 1998) (Figure 15A). Importantly, the HIF1α and HIF2α 
expressing cells exhibited increases in melanoma cell line invasion (Figure 15B 
and 15C) and invadopodia formation (Figure 15D, 15E, and Supplemental Figure 
6).  Additionally, HIF2dPA and to a lesser extent HIF1dPA were sufficient to 
increase pSFK levels (Figure 15F).  This reduced potency of HIF1dPA may 
reflect the residual sensitivity of this isoform to proteasome inhibition, and 
consequent lower levels of expression (Hussussian et al., 1994; Kamb et al., 
1994; W. Y. W. Kim et al., 2006).  Nonetheless, cells expressing HIF1dPA had 
increased levels of PDGFRα, while those expressing HIF2dPA had increased 
expression of FAK (Figure 15F), suggesting that expression of HIF1α and HIF2α 
are sufficient for the normoxic upregulation of PDGFRα and FAK respectively.   
 Previous work has identified that physical properties such as cell stiffness 
correlate with the invasive ability of cancer cells (Butcher, Alliston, & Weaver, 
2009; Cross, Jin, Rao, & Gimzewski, 2007; Gray-Schopfer et al., 2006; 
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Michaloglou et al., 2005; Swaminathan et al., 2011) and a variety of biophysical 
techniques including “magnetic tweezers” allow for measurements of cell 
stiffness on living cells.  To determine whether the increased invasiveness 
associated with expression of stabilized HIF1α or HIF2α also correlated with 
alterations in cell compliance, fibronectin-conjugated magnetic beads were first 
allowed to associate with A375 SM cells expressing EGFP, HIF1dPA, or 
HIF2dPA, a magnetic pulse was then applied to each bead, and the resultant 
motion and recovery of the bead position were used to calculate cell stiffness 
(expressed in pascals [Pa]) as previously described [Figure 15G] (J. Li et al., 
2010; Swaminathan et al., 2011).  An extracellular passive microrheology assay 
was also conducted, and obtained measurements of cell stiffness that confirmed 
these findings (Supplemental Figure 7A and 7B).  These results demonstrate that 
not only are HIF1α and HIF2α sufficient to increase cell invasiveness but they 
also significantly decrease cell stiffness.        
 
HIF1α and HIF2α induced invasion is dependent on PDGFRα and FAK 
respectively 
 In order to determine whether HIFα induced invasion is dependent on 
PDGFRα or FAK we assessed the effect of silencing PDGFRα or FAK on the 
invasive ability of A375 SM and WM2664 cells expressing stabilized versions of 
HIF1α or HIF2α.  To this end, we first verified efficient knock-down of PDGFRα 
or FAK in cells expressing stabilized HIF1α or HIF2α (Figure 16A).  In keeping 
with the model that HIF1α and HIF2α specifically regulate PDGFRα and FAK 
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respectively, we saw that knock-down of PDGFRα resulted in decreased pSFK 
only in cells expressing stabilized HIF1α while knock-down of FAK decreased 
pSFK in cells expressing stabilized HIF2α (Figure 16A).  Moreover, consistent 
with the notion that HIF1α and HIF2α induced invasion are specifically 
dependent upon PDGFRα and FAK respectively, knockdown of PDGFRα 
selectively inhibited the invasive ability of the melanoma cell lines expressing 
HIF1dPA (Figure 16B, 16C, and 16D) while knockdown of FAK only inhibited the 
invasive ability of the melanoma cell lines expressing HIF2dPA (Figure 16B, 16C 
and 16D).  In addition, consistent with the model that both HIF1α and HIF2α 
mediate their invasive effects via SRC, we noted that SRC inhibition with 
dasatinib (100nM) was sufficient to block the invasion of A375 SM and WM2664 
cells expressing stabilized HIF1α or HIF2α (Supplemental Figure 8A, 8B, and 
8C).  These data in aggregate demonstrate that PDGFRα is responsible for 
HIF1α mediated invasion while HIF2α mediates invasion through FAK and that 
both HIF1α and HIF2α require SRC for invasion.    
 
HIF1α and HIF2α regulate expression of MMPs implicated in invadopodia 
formation.   
 One of the primary features that distinguish invadopodia from other 
plasma membrane protrusions such as filopodia or lamellipodia is the ability to 
degrade the extracellular matrix (ECM) (Burdette-Radoux et al., 2004; Murphy & 
Courtneidge, 2011).  This focal ECM degradation (primarily mediated by matrix 
metalloproteases [MMPs]) allows the coordinated destruction of the ECM with 
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cellular motility and invasion.  In this regard, both a membrane bound MMP, 
MT1-MMP (membrane type 1 MMP, also known as MMP14), as well as secreted 
MMPs, MMP2 and MMP9, co-localize with active invadopodia and are key 
determinants of invadopodia formation (Murphy & Courtneidge, 2011; Wu et al., 
2003).   Significantly, we found that endogenous HIF1α was necessary for the 
hypoxic expression MT1-MMP and that HIF1dPA could directly enhance 
normoxic MT1-MMP expression.  By contrast, manipulations of HIF2α failed to 
alter MT1-MMP levels (Figure 17A, 17B, and 17C) but specifically regulated 
MMP2 expression (Figure 17A, 17B, and 17D).  Therefore, not only do HIF1α 
and HIF2α regulate SRC activation but also the expression of key MMPs 
involved in invadopodia-associated ECM degradation.  
To address whether the regulation of MT1-MMP and MMP by HIF1α and 
HIF2α had a functional effect on melanoma invasion we performed RNAi against 
MT1-MMP or MMP2 in our cell lines expressing stabilized HIF1α (HIF1dPA) and 
HIF2α (HIF2dPA) [Figure 17E].  We had hypothesized that knock-down of MT1-
MMP or MMP2 would decrease HIF1α and HIF2α mediated invasion 
respectively.  Unexpectedly, knock-down of either MT1-MMP or MMP2 resulted 
in a decrease of both HIF1α and HIF2α mediated invasion. (Figure 17F, 17G, 
and 17H).  These results suggest that while HIF1α and HIF2α are necessary and 
sufficient to regulate MMP2 and MT1-MMP, the levels of MT1-MMP and MMP2 
seen under normoxia (Figure 17B) are adequate to mediate invasion. 
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Knock-down of Hif1α and Hif2α reduces the hypoxia-induced invasion of cell 
lines derived from Braf-activated, Pten-deficient murine melanomas. 
 Collectively our data demonstrate that HIF1α and HIF2α regulate a 
transcriptional program of genes involved in the formation of active invadopodia, 
cancer cell invasion, and cellular stiffness.  To determine whether Hif1α and 
Hif2α behaved similarly in a defined genetic background, we generated cell lines 
from two independent Pten; Braf melanomas (2130 and 2460).  The cells 
expressed Tryp1 protein (Supplemental Figure 9A) and had deletion of exons 4 
and 5 of Pten (Supplemental Figure 9B) suggesting that they were derived from 
melanocyte lineage and had also undergone TyrCreERT2-mediated recombination 
respectively.   
Loss of PTEN and activation of BRAF are expected to result in increased 
levels of HIF1α as a consequence of PI3K and MEK/ERK upregulation 
respectively (Blancher et al., 2001; D DD Sarbassov et al., 2005; Harris, 2002; 
Kumar et al., 2007; Restuccia & Hemmings, 2010; Sodhi et al., 2001; Yecies & 
Manning, 2011).  In keeping with this notion we saw that pharmacologic inhibition 
of either BRAF or PI3K with vemurafenib and PIK90 respectively downregulated 
not only HIF1α but also HIF2α levels (Figure 18A) suggesting that these 
oncogenic pathways contribute to the activation of HIF1α and HIF2α under 
conditions of hypoxia.     
Finally, consistent with the findings in our human melanoma cell lines, 
hypoxia significantly increased the invasiveness of the Pten; Braf melanoma cell 
lines (2130 and 2460) through matrigel (Figure 18B and 18C).  Moreover, knock-
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down of Hif1α and Hif2α was sufficient to decrease the hypoxic invasion of Pten; 
Braf melanoma cell lines (Figure 18D, 18E, and 18F).  These results therefore 
substantiate the conclusion that Hif1α and Hif2α are necessary for hypoxia-
induced invasion in a defined genetic background of melanoma cell lines derived 
from murine Pten; Braf tumors. 
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D.  DISCUSSION 
We found that while inactivation of Hif1α or Hif2α did not affect the 
initiation or progression of Pten; Braf melanomas, it significantly reduced the 
incidence of lymphatic metastases.  Consistent with these findings, we see that 
HIF1α and HIF2α expression are increased in thick melanomas and metastases 
from patients and that they are both necessary and sufficient for the invasion and 
invadopodia formation of melanoma cell lines.  Moreover, HIF1α and HIF2α 
activate distinct transcriptional programs that converge to activate SRC and 
coordinate ECM degradation via PDGFRα / MT1-MMP and FAK / MMP2 
respectively.  Finally, we demonstrate that hypoxia activates SRC, increases the 
invasiveness of cell lines derived from Pten; Braf melanomas, and that hypoxia-
induced invasion of these cells can be abrogated by knock-down of Hif1α or 
Hif2α.  Collectively these findings demonstrate that while HIF1α and HIF2α do 
not impact primary melanoma initiation or progression, they promote melanoma 
cell invasion, invadopodia formation, and metastases through distinct yet 
convergent transcriptional programs. 
Previous work examining the angiogenic profile of malignant melanomas 
shows that a significant percentage of human melanomas express detectable 
levels of HIF1α and HIF2α by immunohistochemistry, but that only levels of 
HIF2α correlate with VEGF expression and a poor prognosis (Giatromanolaki et 
al., 2003; Tsao et al., 2004).  Other work has confirmed that both mouse and 
human skin is relatively hypoxic and that, at least in the context of Ink4a/Arf 
deficient mouse melanocytes, hypoxia, and specifically stabilized HIF1α, can 
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cooperate with constitutively active AKT in transformation (Bedogni et al., 2005; 
Dankort et al., 2009).  Whether HIF2α can mediate a similar effect was not 
examined.  In our own studies we have stained a TMA consisting of a large 
sample of patients and with a spectrum of melanocytic lesions ranging from 
benign nevi to metastatic melanomas and show that both HIF1α and HIF2α 
expression appears to increase with melanoma metastases.  In addition, we 
have examined whether either loss of Hif1α or Hif2α impacted the initiation of 
Pten; Braf melanomas in GEM models.  We found that inactivation of Hif1α or 
Hif2α did not affect either tumor formation or the rate of melanoma growth after 
their formation.  While there are distinct differences in the systems utilized (i.e. 
soft agar assays and xenografts versus an in vivo autochthonous model) as well 
as the genetic background of the cells (i.e. constitutively activated Akt and 
Ink4a/Arf deletion versus Pten loss and mutant Braf activation), our results 
suggest that, at least in a GEM model of melanoma initiated by Pten loss and 
Braf activation, inactivation of Hif1α or Hif2α did not appreciably affect 
melanocyte transformation or melanoma progression. 
Our in vitro studies in both human melanoma cell lines as well as the cell 
lines derived from Pten; Braf murine melanomas suggest that HIF1α and HIF2α 
are critical nodes that mediate the hypoxia-induced motility and invasiveness of 
melanoma cells.  This work delineates the novel pathways activated by HIF1α 
and HIF2α that mediate actin nucleation and ECM degradation at the forefront of 
invadopodia and shows for the first time that HIF1α and HIF2α are necessary 
and sufficient for invadopodia formation. Notably, our data indicate a novel 
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paradigm, that HIF1α and HIF2α act to promote a metastatic program through 
distinct pathways.  Specifically, HIF1α induces SRC activity and ECM 
degradation via PDGFRα and MT1-MMP, while HIF2α signals to SRC via FAK 
and promotes ECM remodeling through MMP2.   Therefore the transcriptional 
suite of genes activated by HIF1α and HIF2α in response to hypoxia coordinate 
the two processes that define invadopodia: 1) actin nucleation at cell membrane 
protrusions and 2) expression of proteases involved in the degradation of the 
ECM (Murphy & Courtneidge, 2011; Tabernero et al., 2008).  Moveover, these 
HIF-dependent increases in invasion and invadopodia formation are 
accompanied by decreases in cell stiffness, a physical property of cells that has 
been previously shown to inversely correlate with the invasive capacity of cells 
(Butcher et al., 2009; Cross et al., 2007; Margolin et al., 2005; Swaminathan et 
al., 2011).  Whether these HIF-induced alterations in cell compliance are a result 
of the same signaling pathways affecting HIF-induced invasion has yet to be 
determined.          
There are striking clinical similarities between malignant melanoma and 
renal cell carcinoma (RCC), including their hypervascularity and propensity for 
hemorrhagic central nervous system metastases, relative resistance to radiation 
therapy, and most intriguingly, their responsiveness to immunomodulatory agents 
such as IL-2, INFα, and most recently, antibodies directed at the T-cell inhibitory 
ligand/receptor complex, PD-L1 and PD1 (Brahmer et al., 2012; Damsky & 
Bosenberg, 2010; Topalian et al., 2012).  On a molecular level, HIF activation in 
the setting of pVHL inactivation is both necessary and sufficient for RCC 
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tumorigenesis, and HIF appears to mediate the majority of phenotypes seen in 
the setting of VHL deficiency in mice (W. Y. W. Kim et al., 2006; Kondo et al., 
2002; Kondo, Kim, Lechpammer, & Kaelin, 2003; Rankin et al., 2005).  
Interestingly, HIF activation is a consequence of several of the signature genetic 
events found in melanoma.  For example, loss of function mutations of PTEN 
result in an Akt-dependent increase of mTOR activity and the translation of HIFα 
subunits (Bedogni et al., 2005; Sodhi et al., 2001).  HIF is also transcriptionally 
upregulated in tumors with mutant RAS and BRAF as well in tumors 
overexpressing MITF (Blancher et al., 2001; Buscà et al., 2005; Kumar et al., 
2007; Sodhi et al., 2001). Intriguingly, a recent report describes a rare germline 
MITF mutation that predisposes to the development of melanoma, RCC, or both 
(Bertolotto et al., 2011).  Perhaps most interestingly, this MITF mutation, Mi-
E318K, prevents its SUMOylation, enhances its chromatin occupancy, and 
appears to upregulate expression of genes involved in melanomagenesis and 
HIF1α (potential effects on HIF2α have yet to be reported). Therefore, the 
germline MITF mutation, Mi-E318K, appears to link two seemingly similar 
cancers on a molecular level, possibly through activation of HIF.   
Hypoxia has been shown to be associated with metastasis in many solid 
tumors, including melanoma.  Our data suggests that this hypoxic induction of 
metastasis may be mediated through HIF1α and HIF2α expression and the novel 
pathways presented.  PDGFRα, FAK, and SRC are kinases and are therefore 
targetable by inhibitors; indeed inhibitors against PDGFRα (Imatinib) and SRC 
(Dasatinib) are FDA approved and are currently being used in the treatment of 
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multiple cancers.  Melanoma patients presenting at early stages of the disease 
may benefit from treatment with these inhibitors to aid in the prevention of 
intravasation and the spread of the primary tumor to the draining lymph nodes.  
We have shown that these pathways are necessary in the invasion and spread of 
the disease, yet whether the expression of HIF1α, HIF2α, PDFGRα, FAK, or 
SRC is necessary for the maintenance of the metastasis once established in the 
lymph node is not yet known.  Further studies will increase our understanding of 
the role these pathways play in metastatic melanoma and how their suppression 
may best benefit patients in the clinic.	  
In summary, our results establish that HIF plays an active role in the 
metastatic progression of melanoma and demonstrate that HIF1α and HIF2α 
activate independent transcriptional programs, which induce invadopodia 
formation, invasion, and decrease cell stiffness.  We demonstrate in an 
autochthonous mouse model of metastatic melanoma that inactivation of Hif1α or 
Hif2α results in a significant reduction in metastases to regional lymph nodes, 
suggesting that these in vitro observations are operational in vivo. This work 
defines two novel HIF target genes, PDGFRA and FAK and is the first 
examination of the role of HIF2α in melanomagenesis.  Importantly, our studies 
for the first time directly link hypoxia, HIF1α, and HIF2α to enhanced invadopodia 
formation, adding another pathologic stimulus to the list of those currently known 
to modify invadopodia assembly and turnover.  In aggregate, our studies define  
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HIF1α and HIF2α as intimately involved in the process of metastasis in malignant 
melanoma and further enforce the notion that the similarities between melanoma 
and RCC extend beyond mere clinical observations and rare germline genetic 
events.   
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E.  MATERIALS AND METHODS 
 
Cell Lines.  Human melanoma cell lines SK Mel 24 and Sk Mel 28 were obtained 
from the American Type Culture Collection (ATCC), RPMI 7951 were obtained 
from Lineberger Comprehensive Cancer Center Tissue Culture Facility (LCCC 
TCF), cell lines A375 and WM2664 were generously gifted by Jack Arbiser 
(Emory University), and the UACC 257 cell line was generously gifted by Maria 
Soengas (CNIO, Spain).  Cells were cultured in either DMEM with the addition of 
10% fetal bovine serum (Benchmark FBS, Gemini Bio-Products) and 
penicillin/streptomycin (Gibco) (A375SM, UACC 257, WM2664, Sk Mel 24, and 
Sk Mel 28) or αMEM with the addition of 10% FBS and penicillin/streptomycin 
(RPMI 7951).  Cells were incubated at 37 deg C in either normoxic (21% O2 and 
5% CO2) or hypoxic (1% O2 and 5% CO2) conditions and medium was changed 
every other day. 
 
siRNA Transfections and shRNA Transductions.  shRNA constructs against 
HIF1α and HIF2α were obtained from the University of North Carolina Lentiviral 
Core Facility (OpenBiosystems).  Sequences listed in Supplemental Table 1.  
siRNA oligos against human HIF1α and HIF2α, FAK, and PDGFRα were 
purchased from ABI technologies and siRNA oligos against murine Hif1α and 
Hif2α were obtained from Dharmacon. siRNA transfections were performed using 
the Invitrogen Lipofectamine siRNAmax kit according to manufacturer’s 
instructions.  Lentiviruses (pLKO) expressing shRNA against HIF1α and HIF2α 
were produced in 293T cells.  Virus was collected after 72 hours and then placed 
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on either A375 SM or WM2664 cells seeded at approximately 70% confluency.  
Puromycin selections (A375 SM at 2ug/ml, WM2664 at 1ug/ml) were performed 
starting at 48 hours. 
 
Stable Cell Lines.  Retroviruses (pBabe-puro) expressing stabilized versions of 
HIF1α or HIF2α were produced in 293T cells.  Virus was collected after 72 hours 
and then placed on either A375 SM or WM2664 cells seeded at approximated 
70% confluency.  Puromycin selections (A375 SM at 2ug/ml, WM2664 at 1ug/ml) 
were performed starting at 48 hours. 
 
Western Blotting.  Melanoma cell lines were grown to subconfluence in 10cm 
dishes and lysed in buffer containing 200mM Tris-HCl pH 8.0, 120mM NaCl and 
0.5% NP-40 in the presence of protease (Roche) and phosphatase (Calbiochem) 
inhibitors.  Whole cell extracts (30ug) were resolved by either 7.5% or 10% 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to a 
nitrocellulose membrane and then probed with the specific antibodies 
(Supplemental Table 2).  Proteins were visualized with enhanced 
chemiluminescence system from Amersham using horseradish peroxidase-
conjugated anti-rabbit or anti-mouse secondary antibody (Thermo-Scientific). 
 
Matrigel Invasion.  Melanoma cell lines were plated in serum-free media 
overnight.  Then either 50,000 or 100,000 cells were seeded into an 8µm 
matrigel chamber (BD Biosciences) with media containing 10% FBS in the well.  
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Cells were allowed to invade for 18 – 36 hours.  Cells that had invaded through 
the matrigel were then stained with the Siemens Staining Kit according to 
manufacturer’s directions.  Matrigel wells were then placed on a glass slide and 
analyzed and photographed using an Olympus IX51 microscope. Representative 
pictures were taken of each matrigel well quadrant and the number of cells that 
had invaded into the matrigel were determined using ImageJ. 
 
Invadopodia Labeling and Immunofluorescence.   
Active invadopodia were defined as co-localization of F-actin (phalloidin staining), 
cortactin, and degradation of fibronectin.  Immunofluorescence microscopy was 
used to visualize the following: human fibornectin (BD Biosciences) was coupled 
to Alexa Fluor 568 using a protein labeling kit (A10238 Molecular Probes).  A 50-
ug/ml solution was prepared in phosphate-buffer saline (PBS) and incubated on 
cross-linked gelatin (300 Bloom) (Sigma) on glass coverslips.  Cells were seeded 
onto coverslips, incubated for 18-24 h, fixed in 4% paraformaldehyde for 20 
minutes, permeabilized in PBS containing 0.5% Triton X-100 for 5 min, blocked 
in PBS containing 3% bovine serum albumin (BSA) for one hour, and then 
incubated with phalloidin (indicator of F actin) or antibody specific to cortactin for 
2 hours.  Samples were then incubated with fluorophore-conjugated secondary 
antibodies for 1 hour.  Finally, coverslips were mounted with Fluorsave reagent 
(Calbiochem).  Experiments were observed using a LSM 710 laser scanning 
confocal microscope (Carl Zeiss, Germany), and images were processed by 
Photoshop software (Adobe Systems) and Image J.  
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Mouse Colony and Treatment.  Animals were generated and genotyped as 
previously described (Dankort et al., 2009) and were in a mixed background.  
Mice were housed and treated in accordance with protocols approved by the 
institutional care and use committee (IACUC) for animal research at the 
University of North Carolina.  To generate focal tumors, six-week old animals 
were treated with 1ul of 20mM 4-OH Tamoxifen (Sigma H7904) at the base of 
their tail.  Tumor growth and survival was assessed three times per week by 
caliper measurements of tumor areas (width^2*length)/2 [mm2].  Mice were 
sacrificed once the tumor had reached a volume of 1.2 cm3.  
 
Mouse Melanoma Cell Line Generation To generate mouse tumor cell lines, 
tumor samples were washed in PBS containing 20% penicillin/streptomycin and 
then dissociated in 5ml of 0.25% Trypsin for 15 mins at 37 deg C.  Samples were 
then collected with 10ml of RPMI 1640 with 10% FBS and penicillin/streptomycin 
in a 15ml conical and were allowed to settle for 15 min at room temperature.  The 
resulting supernatant and pellet were plated on separate 10cm plates.  Media 
was changed every three days.  In order to eliminate fibroblast contamination, 
samples were trypsinzed with 0.05% Trypsin-EDTA every week and the 
fibroblasts were washed off with PBS.  Resulting mouse tumor cell lines were 
confirmed using PTEN genotyping (Primers listed in Supplemental Table 2).  
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Real-Time PCR.  Total RNA was extracted from cells at 75-90% confluency 
using RNeasy Mini Kit (Qiagen) and were reverse transcribed using ImProm-II 
Reverse Transcription System (Promega).  Resulting cDNA were analyzed in 
triplicates using TaqMan 2X Universal PCR Master Mix (ABI).  Relative mRNA 
concentrations were determined by 2-(Ct-Ct), where Ct is the mean threshold cycle 
difference after normalizing to 18S values.  Primers used for PCR were 
purchased from ABI Technologies. 
 
Experimental Lung Metastasis Assay.   A375 SM cells stably transduced with 
shRNA constructs against either HIF1α, HIF2α, or a nonspecific control were 
harvested by brief exposure to 0.05% trypsin EDTA solutions (Gibco).  Cells 
were washed and resuspended in Ca2+- and Mg2+ -free Hanks’ balanced salt 
solution (HBSS Gibco).  A total of 5 x 105 cells in 0.2ml of HBSS were injected 
into the lateral vein of nude mice.  8 weeks later, the animals were sacrificed and 
the lungs were removed, washed in Phosphate Buffered Solutions (PBS Cellgro), 
and fixed in 10% buffered formalin solution (Sigma) overnight to facilitate 
counting of surface tumor nodules.   
 
Magnetic tweezers assay 
Cultures of A375 SM cells were plated on collagen coated glass coverslips and 
grown to 50-80% confluence.  4.5 µm Tosylactivated magnetic beads (Invitrogen) 
were conjugated with human fibronectin, and incubated with the cells for 10 min.  
The 3D force microscope system was used to apply 50-100 pN of force to each 
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bead for 5 sec, and the resultant motion and recovery recorded at 30 frames per 
second.  Cells were used for as many separate fields of view could be recorded 
within one hour.  Bead position was analyzed using Video Spot Tracker software 
(http://cismm.cs.unc.edu), and fit to a Jeffrey’s model for stiffness, as described 
previously (Swaminathan et al., 2011). 
 
Tissue Microarray 
Antibodies and Immunohistochemistry 
Rabbit polyclonal anti-HIF1α and HIF2α antibodies were from Novus Biologicals 
(Littleton, CO) and Eton Bioscience Inc (San Diego, CA), respectively.  
IHC was carried in the Bond Autostainer (Leica Microsystems Inc.  Norwell, MA). 
Slides were dewaxed in Bond Dewax solution (AR9222) and hydrated in Bond 
Wash solution (AR9590). Antigen retrieval for both antibodies was performed at 
100ºC in Bond-Epitope Retrieval solution 1 pH-6.0 (AR9961) 30 min for HIF1α 
and 40 min HIF2α.  Detection was performed using Bond™ Polymer Refine Red 
Detection (DS9390). Stained slides were dehydrated and coverslipped. Positive 
and negative controls (no primary antibody) were included for each antibody. 
 
Tissue microarray (TMA) construction 
The previously described nevus>melanoma progression TMA (Nazarian, Prieto, 
Elder, & Duncan, 2010) was used to stain for HIF1α and HIF2α. In addition, 
melanoma cases metastatic to brain, lung, and liver were obtained from the UNC 
Hospitals surgical pathology archive to construct the UNC TMA 69A1 (UNC IRB-
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approved protocol 08-0242). H&E stained slides of the selected cases were 
reviewed by a surgical pathologist (C.R.M.), and representative areas of tumor 
and adjacent normal tissues were circled for coring. TMA block, containing 
triplicate cores (0.6 mm) of melanoma metastases was constructed. TMA was 
cut into 4 micron-thick sections and placed on positively charged glass slides.  
 
Digital imaging and image analysis 
Stained TMA and were digitally imaged at 20 × magnifications using the Aperio 
ScanScope XT (Aperio Technologies, Vista, CA). TMA slides were de-arrayed to 
visualize individual cores, using TMA Lab (Aperio). Digital images were stored 
and evaluated by the pathologist (C.R.M.) within the Aperio Spectrum Database 
using the following scoring system: 0 = neg; 1+ = cytoplasmic staining; 2+ = 
weak nuclear staining; 3+ = strong nuclear staining. 
 
Statistical Analysis 
Statistical analysis of percent living (Figure 1B) and tumor-free survival 
(Supplemental Figure 1D) were performed using a log-rank test.  For the TMA 
studies (Figure 1C and 1D) Wilcoxon Rank-Sum tests were used to compare the 
expression between two groups. All statistical analyses were carried out in R 
(http://cran.r-project.org/).  All other statistical comparisons were done using a 2-
sided t-test.  
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Study Approval 
Mice were housed and treated in accordance with protocols approved by the 
institutional care and use committee (IACUC) for animal research at the 
University of North Carolina.   
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F.  SUPPLEMENTAL METHODS 
 
Immunohistochemistry.  
Assistance in sample processing was provided by the University of North 
Carolina Center for Gastrointestinal Biology and Disease.  Tumors, lymph nodes, 
spleens, and lungs were fixed in 10% formalin, embedded in paraffin, sectioned, 
deparaffinized (Histoclear, National Diagnostics), and stained using H&E for 
histological analysis. Slides were counterstained with hematoxylin and then 
mounted with Cytoseal XYL (Richard-Allan Scientific).  The Translational 
Pathology Laboratory (TPL) at University of North Carolina Chapel Hill scanned 
in the slides at 20X objective, which were then analyzed using Spectrum 
software (Aperio Technologies, Vista, CA).  CD31 antibody was purchased from 
Abcam (AB28364), used at a dilution of 1:50 and staining was performed by the 
TPL. 
 
 
Quantification of melanin within lymph node metastasis.   
Lymph nodes were stained with H&E by the UNC Center for GI Biology and 
Disease (CGDB).  Slides were scanned in by TPL and analyzed using Spectrum 
software as above.  15-20 representative pictures were taken at 20X objective 
from lymph nodes from multiple mice of each cohort: Pten; Braf, Pten; Braf; 
Hif1L/L, and Pten; Braf; Hif2L/L.  A blinded reviewer (B.K.) then quantified the 
percentage of melanin within the subcapsular sinus of each lymph node. 
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Chromatin Immuoprecipitation and Real Time PCR.   
Chromatin for ChIP was prepared from A375 SM melanoma cells incubated 
under either normoxic (21% O2) or hypoxic (1% O2) conditions by fixing the cells 
in 1% formaldehyde for 10 minutes followed by quenching with 125mM glycine 
for 5 minutes.  Cells were sonicated and then pelleted to isolate the chromatin.  
ChIP was performed using anti-HIF1α (Novus Biologicals NS100-134), anti-
HIF2α (Novus Biologicals NB100-122) and anti-IGG antibody (Cell Signaling 
2729S).  Briefly, 4µg of the appropriate antibody was incubated with Protein A/G 
UltraLink Resin (Thermo Scientific) and allowed to bind for each ChIP reaction.  
Equivalent amounts of chromatin were added to the antibody-linked beads and 
incubated overnight at 4C.  Supernatant was then collected and reverse cross-
linked for analysis by RT-PCR.   DNA were analyzed in duplicate using 
QuantiTect SYBR Green RT-PCR Kit (Qiagen).  Relative concentrations were 
determined by 2-(Ct-Ct), where Ct is the mean threshold after normalizing to input 
levels.  Primers used for PCR were designed from HRE elements located in the 
promoter regions of PDGFRα and FAK (Supplementary Table 4).  Positive and 
negative controls for both HIF1α and HIF2α were used (ENGL3 for HIF1α, 
AARCD3 HIF2α, and an upstream region of the VEGF promoter for the negative 
control). 
 
Wound closure assay 
A375 SM and WM2664 cells were plated and allowed to reach near confluence.  
A scratch was generated in a uniform manner and the cells were placed in 
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normoxia or hypoxia for 16 hours.  Representative photomicrographs of the 
wound closure were taken using an Olympus IX51 microscope.  Quantification of 
wound closure was performed using ImageJ software. 
 
Extracellular Passive Microrheology.   
Passive measurements used microbeads (2 µm diameter, Invitrogen) coated with 
fibronectin to form attachment to integrin receptors on the surface of the cells.  
Brownian motion of the beads was tracked using Video Spot Tracker 
(CISMM.org) and the mean squared displacement (MSD) of the trajectories was 
computed using  
 <r2τ>  =  <$%&>  =  <[xt+τ−  x(t)]2+  [yt+τ−  y(t)]2>   
 
where t is the elapsed time and τ is the time lag. The complex, frequency-
dependent shear modulus , G*(ω), was calculated from the MSD using the 
generalized Stokes-Einstein relation 
 G∗ω=  kβ  Tπiωa  <r2τ> 
 
where a is the bead radius and ω is the angular frequency, related to the time lag 
through ω = 2/ τ. Viscoelastic mechanical response to thermal motion was 
calculated from 
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|G∗ω|2=G′(ω)2+  G′′(ω)2   
 
where G’(ω) and G’’(ω) describe the elastic and viscous contribution, 
respectively.  Values for G’ were reported at a time lag of 1 second, the 
maximum timescale where thermal fluctuations are predominately Brownian. 
Video data was acquired at 54 frames per second using a high throughput 
microscope system described previously (Spero et al., 2008). A two-sided 
student t-test was performed on the value of the MSD at the 1-second timescale 
to evaluate statistical differences between cell populations. 
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G.  Figures
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Figure 11.  Inactivation of Hif1! or Hif2! does not affect initiation of the survival or growth of Pten; Braf 
melanomas but abrogates lymph node metastases.  (A) Representative gross images as well as low and high-
power photomicrographs of hematoxylin and eosin stained Pten; Braf, Pten; Braf; Hif1, and Pten; Braf; Hif2 
melanomas taken at gross, 10X, and 20X magnification. (B) Kaplan Meier survival curve of cohorts of mice of the 
indicated genotypes (Pten; Braf, n=39, Pten; Braf; Hif1, n=20, and Pten; Braf; Hif2, n=28).  P = 0.6585, log-rank test. 
(C and D) Tissue Microarray (TMA) analysis of HIF1! and HIF2! expression in melanocytic lesions (E and F). 
Representative gross images, low and high-power photomicrographs, and quantification of lymph node metastases 
from the indicated genotypes Pten; Braf (27/39), Pten; Braf; Hif1 (2/13), and Pten; Braf; Hif2 (4/15) taken at gross, 
10X, and 20X magnification. Error bars = SEM. ** P < 0.005. 
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Figure 12. Hypoxia enhances melanoma cell invasion and invadopodia formation.  (A) The indicated cell lines 
were cultured in normoxia (N: 21% O2) or hypoxia (Hy: 1% O2) overnight.  Whole cell extracts were immunoblotted 
with the indicated antibodies.   (B) Representative photomicrographs of A375 SM and WM2664 cells that have 
invaded through matrigel chambers taken at 10X magnification.  (C) Quantification of A375 SM and WM2664 cells 
that have invaded through matrigel chambers.  (D) Representative immunofluorescence images of A375 SM cells 
plated on Alexa 568 conjugated fibronectin and stained with the indicated antibodies taken at 63X magnification.  
Invadopodia were defined as co-localization of cortactin, F-actin (phalloidin), and degradation of Alexa 568 
fibronectin and are indicated with yellow arrows.  (E) Quantification of the percentage of cells with active 
invadopodia in A375 SM and WM2664 cells cultured overnight in normoxia or hypoxia.  (F) Quantification of the 
number of invadopodia per cell in A375 SM and WM2664 cells cultured overnight in normoxia or hypoxia.  Error 
bars = SEM. **** P < 0.0001, *** P < 0.0005, and * P < 0.05.  
C 
A375 SM WM2664 
F 
D 
A375 SM WM2664 
Cortactin Merged Fibronectin Phalloidin 
N
or
m
ox
ia
 
H
yp
ox
ia
 
A375 SM 
WM2664 
H
yp
ox
ia
 
A375 SM B 
	  	  	   95	  
	  
	  	  	  	  	  	  
sh
NS
sh
HI
F1
!
sh
HI
F2
!
0
5
10
15
20
25
lu
ng
 m
et
s 
pe
r m
ou
se *
**
siN
S
siH
IF1
!
siH
IF2
!
siN
S
siH
IF1
!
siH
IF2
!
0
50
100
150
%
 a
ct
iv
e 
in
va
do
po
di
a
***
** ***
***
siN
S
siH
IF1
!
siH
IF2
!
siN
S
siH
IF1
!
siH
IF2
!
0
100
200
300
400
ce
lls
 p
er
 fr
am
e
*
** **
***
Figure 13. 
Figure 13. Knock-down of HIF1! or HIF2! reduces the hypoxia-induced invasion and invadopodia 
formation of melanoma cell lines.  (A) A375 SM and WM2664 cells were transfected with siRNAs against 
HIF1!, HIF2!, or a non-specific sequence (NS). Whole cell lysates were immunoblotted with the indicated 
antibodies. (B) Representative photomicrographs of A375 SM and WM2664 cells transfected with the indicated 
siRNAs that have invaded through matrigel chambers under hypoxia taken at 10X magnification.  (C) 
Quantification of A375 SM and WM2664 cells transfected with the indicated siRNAs that have invaded through 
matrigel chambers under hypoxia.  (D) Representative immunofluorescence images of siRNA transfected A375 SM 
cells plated on Alexa 568 conjugated fibronectin and stained with the indicated antibodies taken at 63X 
magnification.  Invadopodia were defined as co-localization of cortactin, F-actin (phalloidin), and degradation of 
Alexa 568 fibronectin and are indicated with yellow arrows.  (E) Quantification of the percentage of cells with active 
invadopodia in siRNA transfected A375 SM and WM2664 cells.  (F) Quantification of the number of visible lung 
metastases found in mice tail vein injected with A375 SM cells  (G) Gross representative images of the lungs from 
tail vein injected mice. Yellow arrows indicate lung metastases. Error bars = SEM. *** P < 0.0005, ** P < 0.005, and 
* P < 0.05. 
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Figure 14. 
Figure 14. HIF1! and HIF2! upregulate PDGFR! and FAK and are necessary for hypoxia-induced SFK 
activation.  (A) A375 SM and WM2664 cells were cultured in normoxia (N: 21% O2) or hypoxia (Hy: 1% O2) 
overnight.  Whole cell extracts were immunoblotted with the indicated antibodies.  (B) A375 SM and WM2664 cells 
were transfected with siRNAs against HIF1!, HIF2!, or a non-specific sequence (NS). Whole cell lysates were 
immunoblotted with the indicated antibodies.  (C) Tumor lysate from the indicated cohorts were immunoblotted for 
the indicated antibodies. (D and E) A375 SM and WM2664 cells were transfected with siRNAs against HIF1!, 
HIF2!, or a non-specific sequence and cultured under hypoxia overnight.  Total RNA was used to perform TaqMan 
quantitative real time PCR for PDGFR! and FAK.  (F) A375 SM and WM2664 cells were transfected with siRNAs 
against HIF1!, HIF2!, both HIF1! and HIF2!, or a non-specific sequence. Whole cell lysates were immunoblotted 
with the indicated antibodies. (G) Representative photomicrographs of A375 SM and WM2664 cells transfected with 
the indicated siRNAs that have invaded through matrigel chambers taken at 10X magnification.  (H and I) 
Quantification of A375 SM and WM2664 cells transfected with the indicated siRNAs that have invaded through 
matrigel chambers. Error bars = SEM. *** P < 0.0005, ** P < 0.005, and * P < 0.05.   
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Figure 15. Expression of stabilized HIF1! and HIF2! are sufficient to enhance normoxic melanoma cell 
invasion. (A) A375 SM and WM2664 cells were infected with retrovirus to stably express EGFP or stabilized 
versions of HIF1! (HIF1dPA) or HIF2! (HIF2dPA).  Whole cell extracts were immunoblotted with the indicated 
antibodies.  (B) Representative photomicrographs of A375 SM and WM2664 cells stably expressing EGFP, 
HIF1dPA, or HIF2dPA that have invaded through matrigel chambers taken at 10X magnification.  (C) 
Quantification of A375 SM and WM2664 cells stably expressing EGFP, HIF1dPA, or HIF2dPA that have 
invaded through matrigel chambers. (D) Representative immunofluorescence images of A375 SM cells stably 
expressing EGFP, HIF1dPA, or HIF2dPA and plated on Alexa 568 conjugated fibronectin and stained with the 
indicated antibodies taken at 63X magnification.  Invadopodia were defined as co-localization of cortactin, F-
actin (phalloidin), and degradation of Alexa 568 fibronectin and are indicated with yellow arrows.  (E) 
Quantification of the percentage of cells with active invadopodia in A375 SM and WM2664 cells stably 
expressing EGFP, HIF1dPA, or HIF2dPA. (F) Whole cell extracts from A375 SM and WM2664 cells stably 
expressing EGFP, HIF1dPA, or HIF2dPA were immunoblotted with the indicated antibodies. (G) A375 SM cells 
stably expressing EGFP, HIF1dPA, or HIF2dPA were allowed to adhere to fibronectin conjugated magnetic 
beads, subjected to repeated magnetic pulses and the resultant motion and recovery were quantified and used 
to caluculate cell stiffness in Pascales (Pa). Error bars = SEM.  *** P < 0.0005, ** P < 0.005 and * P < 0.05. 
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Figure 16. 
Figure 16. HIF1! and HIF2! dependent invasion require PDGFR! and FAK respectively.  (A)  A375 SM 
and WM2664 cells stably expressing EGFP, HIF1dPA, or HIF2dPA were transfected with siRNAs against 
PDGFR! and FAK. Whole cell extracts were immunoblotted with the indicated antibodies.  (B) Representative 
photomicrographs of A375 SM and cells stably expressing EGFP, HIF1dPA, or HIF2dPA and transfected with 
indicated siRNA oligos that have invaded through matrigel chambers taken at 10X magnification.  (C) 
Quantification of A375 SM cells stably expressing EGFP, HIF1dPA, or HIF2dPA and transfected with siRNA 
oligos against either PDGFR! or FAK that have invaded through matrigel chambers. (D) Quantification of 
WM2664 cells stably expressing EGFP, HIF1dPA, or HIF2dPA and transfected with siRNA oligos against 
either PDGFR! or FAK that have invaded through matrigel chambers. Error bars = SEM.  *** P < 0.0005 and 
** P < 0.005. 
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Figure 17. 
Figure1 7. HIF1! and HIF2! regulate expression of MMPs implicated in invadopodia formation.  (A) A375 
SM and WM2664 cells were transfected with siRNAs against HIF1!, HIF2!, or a non-specific sequence. Whole 
cell lysates were immunoblotted with the indicated antibodies.  (B) A375 SM and WM2664 cells were infected with 
retrovirus to stably express EGFP or stabilized versions of HIF1! (HIF1dPA) or HIF2! (HIF2dPA).  Whole cell 
extracts were immunoblotted with the indicated antibodies.  (C and D) A375 SM and WM2664 cells were 
transfected with siRNAs against HIF1!, HIF2!, or a non-specific sequence.  Total RNA was used to perform 
TaqMan quantitative real time PCR for MT1-MMP and MMP2. (E) A375 SM cells stably expressing HIF1dPA and 
HIF2dPA were transfected with siRNAs against MT1-MMP, MMP2, or a nonspecific sequences. Whole cell lysate 
was immunoblotted with the indicated antibodies. (F) Representative photomicrographs of A375 SM and WM2664 
cells stably expressing EGFP, HIF1dPA, or HIF2dPA and transfected with siRNA oligos against either MT1-MMP 
or MMP2 that have invaded through matrigel chambers taken at 10X magnification.  (G and H) Quantification of 
A375 SM and WM2664 cells stably expressing EGFP, HIF1dPA, or HIF2dPA and transfected with siRNA oligos 
against MT1-MMP or MMP2 that have invaded through matrigel chambers. Error bars = SEM.  *** P < 0.0005, ** 
P < 0.005, and * P < 0.05. 
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Figure 18. Knock-down of Hif1! and Hif2! reduces the hypoxia-induced invasion of cell lines derived from 
Braf-activated, Pten-deficient melanomas.  (A) 2460 Pten; Braf melanoma cells were treated with the indicated 
doses of Vemurafenib, PIK-90, or DMSO overnight.  Whole cell lysates were immunoblotted with the indicated 
anitobodes.  (B) Representative photomicrographs of 2130 and 2460 Pten; Braf melanoma cells that have invaded 
through matrigel chambers under hypoxia or normoxia taken at 10X magnification.  (C) Quantification of 2130 and 
2460 Pten; Braf melanoma cells that have invaded through matrigel chambers. (D) 2130 and 2460 Pten; Braf 
melanoma cells were transfected with siRNAs against murine Hif1! or Hif2! and immunoblotted with the indicated 
antibodies. (E) Representative photomicrographs of 2130 and 2460 Pten; Braf melanoma cells that were 
transfected with siRNAs against murine Hif1! or Hif2! and allowed to invade through matrigel chambers under 
hypoxia taken at 10X magnification.  (F) Quantification of 2130 and 2460 Pten; Braf melanoma cells that were 
transfected with siRNAs against murine Hif1! or Hif2! and allowed to invade through matrigel chambers under 
hypoxia.  Error bars = SEM. *** P < 0.0005, ** P < 0.005, and * P < 0.05.   
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Supplemental Figure 1. 
Supplemental Figure 1.  Inactivation of Hif1! or Hif2! does not affect tumor free survival. (A) 
Representative pictures of the initial pigmented lesions on mice from the indicated genotypes seen 
approximately 3 weeks after tamoxifen treatment. (B) Tumor lysates from the indicated genotypes were 
immunoblotted for the indicated antibodies. (C) Tumor volume of primary melanomas from the indicated 
genotypes (Pten; Braf, n=39, Pten; Braf; Hif1, n=20, and Pten; Braf; Hif2, n=28). (D) Kaplan-Meier survival 
curve of cohorts of mice of the indicated genotypes (Pten; Braf n=39, Pten; Braf; Hif1 n=20, and Pten; Braf; 
Hif2 n=28).  P = 0.7489, log-rank test. (E) Tumor weight of primary melanomas from the indicated genotype 
(Pten; Braf, n=5, Pten; Braf; Hif1, n=5, Pten; Braf; Hif2, n=5). (F and G) CD31 staining and quantification of 
CD31+ vessels per high power field from the indicated genotypes taken at 20X magnification (Pten; Braf, 
n=10 Pten; Braf; Hif1, n=8, and Pten; Braf; Hif2, n=8). (H)  Quantification of the percent area of the 
subcapsular sinus of the lymph node expressing melanin from the indicated genotypes. Error bars = SEM ** 
P < 0.005, and * P < 0.05.  
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Supplemental Figure 2. 
IB: HIF1! 
IB: Ku80 
Hy N Hy N Hy N Hy N Hy N Hy N Hy N 
Supplemental Figure 2.  A subset of melanoma cell lines express HIF1! in normoxia.  The indicated 
cell lines were cultured overnight under normoxia or hypoxia.  Whole cell extracts were prepared and 
immunoblotted with the indicated antibodies.  This is a longer exposure of the immunoblot represented in 
Figure 2A.   
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Supplemental Figure 3. 
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Supplemental Figure 3.  Hypoxia promotes melanoma cell motility in a HIF1! and HIF2! dependent 
manner. (A) A375 SM and WM2664 cells were plated and allowed to reach near confluence.  A scratch was 
generated in a uniform manner and the cells were placed in normoxia or hypoxia for 16 hours.  Representative 
photomicrographs taken at 10X magnification demonstrate the degree of wound closure.  (B) Quantification of 
wound closure from A375 SM and WM2664 cells cultured under normoxia or hypoxia. (C) A375 SM and WM2664 
cells transfected with shRNAs against HIF1! and HIF2! were plated and allowed to reach near confluence.  A 
scratch was generated in a uniform manner and the cells were placed in hypoxia for 16 hours.  Representative 
photomicrographs taken at 10X magnification demonstrate the degree of wound closure.  (D) Quantification of 
wound closure from A375 SM and WM2664 cells infected with shRNAs against HIF1! and HIF2! cultured under 
hypoxia. (E) A375 SM and WM2664 cells infected with shRNAs against HIF1! and HIF2! were plated and 
allowed to reach near confluence.  A scratch was generated in a uniform manner and the cells were placed in 
normoxia for 16 hours.  Representative photomicrographs taken at 10X magnification demonstrate the degree of 
wound closure.  (F) Quantification of wound closure from A375 SM and WM2664 cells transfected with shRNAs 
against HIF1! and HIF2! cultured under normoxia.  Error bars = SEM, *** P < 0.0005, ** P < 0.005, and * P = 
0.05   
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Supplemental Figure 4. 
Supplemental Figure 4.  Hypoxia promotes melanoma cell invasiveness in a HIF1! and HIF2! 
dependent manner. (A) Representative photomicrographs taken at 10X magnification of A375 SM and 
WM2664 cells infected with the indicated shRNAs that have invaded through matrigel chambers under 
normoxia.  (B) Quantification of A375 SM and WM2664 cells infected with the indicated shRNAs that have 
invaded through matrigel chambers under normoxia. (C) Quantification of the number of invadopodia per 
cell in siRNA transfected A375 SM and WM2664 cells.  Error bars = SEM, *** P < 0.0005 and ** P < 0.005.  
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Supplemental Figure 5. 
A 
Supplemental Figure 5. HIF1! and HIF2! directly regulate PDGFR! and FAK transcription. (A and 
B) Total RNA was prepared from primary tumors from Pten; Braf, Pten; Braf; Hif1L/L, and Pten; Braf; Hif2L/L 
mice and used to perform TaqMan quantitative real time PCR for Pdgfra and Fak. (C) A375 SM and 
WM2664 cells were transfected with siRNAs against HIF1!, HIF2!, or a non-specific (NS) sequence.  
Total RNA was used to perform TaqMan quantitative real time PCR for TWIST1. (D) A375 SM and 
WM2664 cells were transfected with siRNAs against HIF1!, HIF2!, or a non-specific sequence. Whole 
cell lysates were immunoblotted with the indicated antibodies. (E) Chromatin immunoprecipitation (ChIP) 
of HIF1! or HIF2! at the promoter of PDGFRA under normoxia and hypoxia. (F) ChIP of HIF1! or HIF2! 
at the promoter of FAK under normoxia and hypoxia. (G and H) Positive (ENGL3 and AARCD3, for HIF1! 
and HIF2! targets respectively) and negative (Upstream VEGF) controls for ChIP of HIF1! or HIF2! under 
normoxia and hypoxia. Error bars = SEM, ** P < 0.005, and * P = 0.05  
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Supplemental Figure 6 
A375 SM WM2644 
21% O2 
Supplemental Figure 6. HIF1! and HIF2! stabilization at normoxia increases invadopodia formation.  
Quantification of the number of invadopodia per cell in A375 SM and WM2664 cells stably expressing EGFP, 
HIF1dPA, or HIF2dPA.  Error bars = SEM, *** < P 0.0005 and ** P < 0.005. 
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Supplemental Figure 7. 
A 
Supplemental Figure 7. Stabilized HIF1! and HIF2! decrease the stiffness of A375 SM cells. (A) 
Average mean squared displacement (MSD) as a function of time lag from 0.1 to 10 seconds.  The EGFP, 
HIF1dPA, and HIF2dPA MSD curves are the average of 557, 519, and 190 individual particles, 
respectively.  (B) Average MSD at 1-second timescale.  Inside each bar is the root mean squared (RMS) 
displacement and the elastic shear modulus (G’) at the 1-second time lag. The quantity for RMS 
displacement describes the average effective radius of the motion of a particle; the quantity for G’ is an 
effective modulus computed using the generalized Stokes-Einstein relation (see supplemental methods). 
Error bars = SEM. * P < 0.0001. 
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Supplemental Figure 8. 
A 
Supplemental Figure 8. Inhibition of SRC activity decreases HIF-induced invasion. (A) 
Representative photomicrographs taken at 10X magnification of A375 SM and WM2664 cells stably 
expressing EGFP, HIF1dPA, or HIF2dPA and treated with either DMSO or 100nM Dasatinib that have 
invaded through matrigel chambers.  (B and C) Quantification of A375 SM and WM2664 cells stably 
expressing EGFP, HIF1dPA, or HIF2dPA and treated with either DMSO or 100nM Dasatinib that have 
invaded through matrigel chambers. Error bars = SEM, **** P < 0.0001 and *** P < 0.0005 
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Supplemental Figure 9. Cell lines derived from primary Pten; Braf melanomas. (A) Whole cell 
extracts from cell lines derived from Pten; Braf melanomas (2130 and 2460) were immunoblotted with 
antibodies specific to Trp1.  Whole cell extracts from mouse embryo fibroblasts (MEFs) were used as a 
negative control. (B) Tail DNA (recut) and cells lines of Pten; Braf mice (2130 and 2460) were assessed for 
the presence of Pten loss by primers that specifically detect the Floxed allele as well as the allele after Cre 
mediated recombination (Cre Out). 
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Supplemental Table 1. 
construct seed sequence 
HIF1! 
shHIF1! TGCTCTTTGTGGTTGGATCTA 
HIF2! 
shHIF2! CCATGAGGAGATTCGTGAGAA 
PTEN 
PRIMERS 
CPF1 CTT CGG AGC ATG TCT GGC AAT GC 
R1NEOCP CTG CAC GAG ACT AGT GAG ACG TGC 
PTR13 AAG GAA GAG GGT GGG GAT AC 
ChIP PRIMERS 
PDGFRA Forward TAT TTA CCC CAA CCC AAG CA 
PDGFRA Reverse TGC ATG CAG TTT TCA ATG GT 
FAK Forward CCG AGA GGC TTA AGG AGG TC 
FAK Reverse GCC TCC TCG TCT TCC TCA G 
Antibody Company Catalogue # Dilution 
HIF1! Cell Signaling 3716S 1:1000 
HIF2! Novus Biosystems NB100-122 1:1000 
Ku80 GeneTex GTX70485 1:5000 
pSFK Cell Signaling 2113S 1:1000 
SRC Cell Signaling 2123S 1:1000 
PDGFR! Cell Signaling 5241S 1:500 
FAK Cell Signaling 3285S 1:1000 
MT1-MMP Millipore AB6004 1:1000 
MMP2 Cell Signaling 4022S 1:1000 
MMP9 Cell Signaling 2270S 1:1000 
mHif1a Novus Biosystems NS100-479 1:1000 
mHif2a Novus Biosystems NB100-132 1:1000 
Actin HRP Santa Cruz sc-1615 HRP 1:5000 
Twist Active Motif 61097 1:1000 
TYRP1 Vincent Hearing 1:1000 
pAKT Cell Signaling 4060S 1:1000 
AKT Cell Signaling 9272S 1:1000 
pERK Cell Signaling 9101S 1:1000 
ERK Cell Signaling 9102S 1:1000 
Chapter	  IV	  Discussion	  and	  Future	  Directions	  
The studies presented in this thesis aimed at interrogating the role of the 
hypoxia-inducible factors in malignant melanoma.  Through the use of in vivo 
genetically engineered mouse models and in vitro human and mouse melanoma 
cell lines, we have been able to better understand the functional roles of HIF1α 
and HIF2α in melanoma and its progression to metastasis.   
A previously published GEMM of melanoma had shown that conditional 
activation of Braf and loss of Pten in melanocytes resulted in metastatic 
melanoma (Dankort et al., 2009).  We found that while inactivation of HIF1α or 
HIF2α did not affect the initiation or progression of Pten; Braf melanomas, it 
significantly reduced the incidence of the lymphatic metastases found in the 
control mice.  Consistent with these findings, using a tissue microarray of 
melanoma, we saw that HIF1α and HIF2α expression are increased in thick 
melanomas and metastases from patients.  Experiments performed in vitro 
demonstrated that both HIF1α and HIF2α are necessary and sufficient for the 
invasion and invadopodia formation of melanoma cell lines.  Moreover, HIF1α 
and HIF2α activate distinct transcriptional programs that converge to activate 
SRC and coordinate ECM degradation via PDGFRα / MT1-MMP and FAK / 
MMP2 respectively (figure 19).  Finally, we demonstrated that hypoxia activates
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Src and increases the invasiveness of cell lines derived from Pten; Braf 
melanomas, and that hypoxia-induced invasion of these cells can be abrogated 
by knock-down of Hif1α or Hif2α.  Collectively these findings demonstrate that 
while HIF1α and HIF2α do not impact primary melanoma initiation or 
progression, they promote melanoma cell invasion, invadopodia formation, and 
metastases through distinct yet convergent programs.	  	  
	  	  
Figure 19.  HIF Regulates a Transcriptional Program to Increase Invasion 
in Melanoma.  HIF1α transcriptionally regulates PDGFRα and expression and 
HIF2α transcriptionally regulates FAK expression to increase Src activation 
and actin localization.  To increase ECM degradation, HIF1α regulates 
expression of MT1-MMP and HIF2α regulates expression of MMP2.  These 
pathways combine to increase invadopodia formation and invasion in 
melanoma. 	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A.  HIF expression and metastases 
Studies have shown that both mouse and human melanocytes reside in a 
relatively hypoxic environment and that this hypoxic environment is actually 
beneficial to the survival and growth these cells.  In Ink4a/Arf deficient 
melanocytes, this hypoxia cooperates with Akt in a Hif1α-dependent manner for 
the transformation of melanocytes (Bedogni et al., 2005).  In this study, we 
examined whether either loss of Hif1α or Hif2α impacted the initiation of Pten; 
Braf melanomas in GEM models.  We found that inactivation of Hif1α or Hif2α 
did not affect either tumor formation or the rate of melanoma growth after their 
formation.  While there are distinct differences in the systems utilized (i.e. soft 
agar assays and xenografts versus an in vivo autochthonous model) as well as 
the genetic background of the cells (i.e. constitutively activated Akt and Ink4a/Arf 
deletion versus Pten loss and mutant Braf activation), our results suggest that, at 
least in a GEM model of melanoma initiated by Pten loss and Braf activation, 
inactivation of Hif1α or Hif2α did not appreciably affect melanocyte 
transformation or melanoma progression. 
 Tumor hypoxia has been shown to correlate with metastasis in multiple 
cancers including melanoma (Brown, 1999; Kunz et al., 1999; Rofstad et al., 
2002).  A clinical study looking at angiogenic factors in melanoma as possible 
prognostic indicators showed that while both HIF1α and HIF2α overexpression 
significantly correlated with high VEGF expression, only HIF2α overexpression 
was linked with poor “disease-specific” overall survival (Giatromanolaki et al., 
2003). In this study, we have stained a TMA consisting of a large sample of 
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patients with a spectrum of melanocytic lesions, ranging from benign nevi to 
metastatic melanomas, and show that both HIF1α and HIF2α expression 
appears to increase with melanoma metastasis.  We also saw that while neither 
Hif1α nor Hif2α expression affected the initiation and growth of the primary 
melanoma in the Pten; Braf GEMM, knock-out of either gene resulted in a 
decrease of lymph node metastases.  These results suggest that HIF1α and 
HIF2α are important in the metastatic spread of melanoma, and in particular to its 
spread to the regional lymph nodes. 
 In order to see if this phenotype could be replicated in human melanoma 
cell lines, we moved to in vitro studies of invasion to determine if hypoxia, HIF1α, 
and HIF2α have a similar function to what we saw in vivo.  Our results show that 
hypoxia significantly increased both the motility, as seen though wound closure 
assays, and the invasive capabilities of human melanoma cell lines, as seen 
through matrigel assays.  When we knocked down either HIF1α or HIF2α with 
siRNA, this increased mobility and invasion was lost.  The same phenotype of 
increased invasion was observed in melanoma cell expressing stabilized HIF1α 
and HIF2α at normoxia.  There results suggest that both HIF1α and HIF2α are 
necessary and sufficient for the mobility and invasion of the melanoma cells. 
 While wound closure and matrigel assays are traditional methods at looking 
at the mobilization and invasion capabilities of cell lines in vitro, we wanted to 
look at another assay that would give us more insight into both the invasive and 
metastatic potential of the melanoma cells, to this end we looked at the formation 
of invadopodia.   
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 Invadopodia were first discovered in fibroblasts transformed with Rous 
sarcoma virus (RSV), containing the oncogene Src.  Transformation of the cells 
with the virus caused relocalization of the cytoskeletal proteins vinculin and α-
actinin away from the cell-ECM contact points called focal adhesions and into 
circular clusters called rosettes (David-Pfeuty & Singer, 1980).  Studies would 
show that these rosettes also contained actin and tyrosine phosphorylated 
proteins, were sites of cell adhesion to the ECM with localized expression of Src, 
and that degradation of the ECM occurs at these contact sites (Murphy & 
Courtneidge, 2011).  Invadopodia may therefore allow a cell to coordinate EMC 
degradation with cell motility, facilitating cell migration through tissue 
microenvironments. 
 In this study, we found that hypoxia significantly increased the amount of 
melanoma cells with invadopodia as well as the number of invadopodia formed 
by each cell.  This hypoxic-induction of invadopodia formation was abrogated by 
the knock-down of either HIF1α or HIF2α with siRNA.  We also saw the same 
phenotype of increased invadopodia formation in melanoma cells expressing 
stabilized HIF1α or HIF2α in normoxia.  These results suggest that both HIF1α 
and HIF2α are necessary and sufficient for the formation of invadopodia in 
melanoma cell lines.  
 The results described above demonstrate that HIF1α and HIF2α may play a 
role in the invasive and metastatic potential of melanoma.  One of the first stages 
in metastasis is intravasation, described in Chapter 2.  Our findings suggest that 
both HIF1α and HIF2α may facilitate the ability of melanoma cells, both human 
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and murine, to invade into the ECM and begin the pathway towards metastasis, 
particularly in lymph node metastases as seen in our GEMM.  Melanomas are 
known to be hypoxic, have increased expression of HIF1α and HIF2α associated 
with poor prognosis, and have a propensity to metastasize.  The increased 
expression of HIF1α and HIF2α could be one of the reason for this metastasis as 
HIF has been shown to regulate the expression of genes involved in every step 
of metastasis (as describe in Chapter 2).   
 A future use of the Pten; Braf; Hifα model would be to control HIF1α or 
HIF2α expression in a timely manner, possibly through the use a Tet-On 
regulated HIF1α and / or HIF2α allele.  It has been shown that by treating just the 
tail of the mouse with tamoxifen and then resecting the resulting tumor, Pten; 
Braf tumors are able to metastasize to more sites than the regional lymph nodes 
(Dankort et al., 2009).  By regulating the expression of HIF1α or HIF2α 
expression temporally we would be able to better understand if and how HIF1α 
and HIF2α are regulating each of these steps in melanoma.  
 
B.  HIF and Metastasis to the Regional Lymph Nodes 
 Lymph node metastasis develops in 15-20% of patients with clinically 
localized melanoma of intermediate thickness (Morton et al., 2006).  This 
metastasis is an important prognostic factor in early-stage melanoma with 
patients presenting with nodal metastases being classified as stage III patients 
(Balch, Buzaid, et al., 2001a).  Patients presenting with stage III melanoma have 
a 5-year life expectancy of 20-73%, with decreased survival correlating with 
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increased nodal metastases.  This marker of melanoma progression is well 
studied in the clinic and the methods of lymphangiogenesis and intravasation into 
these new vessels is an important field of research. 
 It is estimated that 80% of metastasis of solid cancers, such as melanoma, 
disseminate through the lymphatic system, while 20% of metastases may occur 
through the circulatory system or direct seeding (Leong et al., 2011).  Malignant 
cells reaching the sentinel lymph node may disseminate further to distal lymph 
nodes, reach systemic circulation, and subsequently form organ metastasis.  In 
melanoma patients, and also breast cancer, sentinel lymph node excision is 
commonly carried out.  Figuring out the pathways involved in these steps of 
metastases could help patients with advanced disease. 
 A key component of lymphangiogenesis is VEGF-C and its receptor 
VEGFR3.  VEGF-C participates in lymphangiogenesis and the maintenance of 
differentiated lymphatic endothelium in adults (Lymboussaki, Olofsson, Eriksson, 
& Alitalo, 1999).  High expression of these two factors in patient samples 
correlate with lymph node metastasis in a number of tumor types (Bedrosian et 
al., 2000; Thiele & Sleeman, 2006).  Hypoxia and HIF1α expression has been 
shown to increase the expression of VEGF-C in human pulmonary artery 
endothelial cells (Balch, Soong, et al., 2001b; Manalo et al., 2005) and to 
correlate with VEGF-C expression and lymphangiogenesis in breast cancer 
(Haass & Herlyn, 2005; Schoppmann et al., 2006).  Finally, HIF1α was found to 
induce both VEGF-C and VEGFR3 expression in lymphatic endothelial cells 
(LECs) (Meier et al., 2002; Y. Y. Min et al., 2011).  Together, these findings 
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suggest that hypoxia and HIF1α play a role in lymphangiogenesis and the spread 
of malignant cancer cells to sentinel lymph nodes.   
 In metastatic melanoma, VEGFR3 expression is significantly higher 
compared to nevi (Mehnert et al., 2010; Mouawad, Spano, Comperat, Capron, & 
Khayat, 2009) while in melanoma xenographs VEGF-C overexpression 
selectively induces intratumoral lymphangiogenesis leading to increased 
metastasis (Achen et al., 2001).  When melanoma cell lines were treated with 
siRNAs against either HIF1α or HIF2α, expression of both VEGF-C and VEGFR3 
decreased, demonstrating that the expression of these two genes is mediated by 
both HIF1α and HIF2α (Spinella, Caprara, Di Castro, & Rosanò, 2012).  
Examining these parameters in our Braf; PTen model would be of potential 
interest (or something like this)>  
 The phenotypes we describe in our study support these findings.  While we 
did not look at the expression of either VEGF-C or VEGFR3 in the GEMM or 
melanoma cell lines, it would be interesting to see if there are indeed decreased 
levels of these genes in the setting of HIF1α or HIF2α loss.   
 We did not see metastasis to any distant organs in our mouse model of 
melanoma.  This could be due to the fact that we had to sacrifice our animals due 
to tumor burden as opposed to the morbidity of the animal.  If the tumors were 
able to continue to grow, or if they were resected and the animals were able to 
continue in the study, it is possible that we would see not only the lymph node 
metastases described in our study, but also distant metastases to organs such 
as the lung and liver.  It is also possible that HIF1α and HIFα expression may 
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facilitate intravasation and lymph node metastasis but are not necessary for 
distant metastases.  While increased levels of HIF1α and HIF2α are seen in 
metastases, as shown by our TMA, increased levels of HIF1α are not found in 
distant metastases (HIF2α levels were not assessed) (Discussions with Stergios 
Moschos).  HIF1α and HIF2α may therefore play a critical role in the initial steps 
of metastasis in melanoma but not in its subsequent dissemination to distant 
organs.  By understanding the pathways affected by HIF1α and HIF2α in the 
ability of melanoma cells to invade and metastasize we may be able to offer 
better treatments to patients presenting with early stages of melanoma in the 
clinic. 
 
C.  HIF expression increased SRC activation 
 Our in vitro studies in both human melanoma cell lines as well as the cell 
lines derived from Pten; Braf murine melanomas suggest that HIF1α and HIF2α 
are critical nodes that mediate the hypoxia-induced motility and invasiveness of 
melanoma cells.  A previous study by Lucien et al. demonstrated that hypoxia 
induced the formation of invadopodia in a fibrosarcoma cell line, however they 
did not look at the effects of either HIF1α or HIF2α expression on the formation 
of these invadopodia (Lucien, Brochu-Gaudreau, Arsenault, Harper, & Dubois, 
2011).  Our studies delineate the novel pathways activated by HIF1α and HIF2α 
that mediate actin nucleation and ECM degradation at the forefront of 
invadopodia and show for the first time that HIF1α and HIF2α are necessary and 
sufficient for invadopodia formation. Notably, our data indicate a novel paradigm:  
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HIF1α and HIF2α act to promote a metastatic program through distinct 
pathways.   
 As mentioned previously, invadopodia were first discovered in fibroblasts 
transformed with Rous sarcoma virus containing the Src oncogene.  Src has 
been found to be necessary for both their form and function.  Src stimulates 
primary actin nucleation, the formation of new actin filaments from actin 
monomers allowing for cell locomotion.  Hypoxia has been shown to induce Src 
in vitro and in vivo (Lluis, Buricchi, Chiarugi, Morales, & Fernandez-Checa, 2007; 
Pham et al., 2009).  pSrc has also been found to be upregulated in metastases 
relative to primary cutaneous melanomas (Homsi et al., 2009).  Our findings 
confirm that while there was no change in total Src levels under hypoxia, we did 
see an increase in activated Src (phosphorylation of residue Tyr416).  This 
hypoxic-induction of Src activity was decreased when either HIF1α or HIF2α 
were knocked-down using siRNA.  Stabilized expression of either HIF1α or 
HIF2α at normoxia confirmed Src activation.  Src inhibition with Dasatinib 
showed a decrease in invasive capabilities in cells with stabilized HIF1α or 
HIF2α indicating that the increase in invasion seen in HIFα stabilized cell lines in 
indeed SRC dependent.  Since both HIF1α and HIF2α are transcription factors, it 
seemed unlikely that they would be directly affecting the activity of Src.  
Therefore, these results suggest that HIF1α and HIF2α are regulating the 
expression of Src activators. 
 Growth factor receptors such as EGFR, PDGFR, and FGFR are known 
regulators of Src (L. Q. L. Jiang et al., 2006) and previous work had shown that 
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Twist1 induced Src-dependent invadopodia formation through the direct 
transcriptional regulation of PDGFRα (Eckert et al., 2011).  TWIST1 is a known 
target of HIF1α (Gort et al., 2008; M.-H. Yang et al., 2008) so this pathway 
seemed an obvious point to start looking for our mechanism.  While our findings 
did not see any change in TWIST1 protein or mRNA levels, we did find that 
HIF1α is activating SRC through the direct transcriptional activation of PDGFα.  
Surprisingly, HIF2α regulates SRC activation through an alternative pathway by 
directly regulating the transcriptional activation of FAK.  These findings are 
interesting as, while HIF1α and HIF2α often share the same targets, such as 
VEGF, in this scenario, HIF1α and HIF2α are both regulating the activation of 
Src through divergent pathways.   
 The degradation of the ECM by MMPs is a known characteristic of 
invadopodia (Murphy & Courtneidge, 2011) and the expression of multiple MMPs 
in both primary tumors and metastases positively correlates with tumor 
progression and poor prognosis (Deryugina & Quigley, 2006).  Both hypoxia and 
HIF have been shown to regulate the expression of multiple MMPs (Jing et al., 
2012; Proulx-Bonneau, Guezguez, & Annabi, 2011; T. T. Xie, Yuan, Yu, Bin B 
Yang, & Dong, 2008).  Our findings suggest that HIF1α is transcriptionally 
regulating MT1-MMP and that HIF2α is transcriptionally regulating MMP2.   
 In summary, HIF1α induces SRC activity and ECM degradation via 
PDGFRα and MT1-MMP, while HIF2α signals to SRC via FAK and promotes 
ECM remodeling through MMP2.   Therefore the transcriptional suite of genes 
activated by HIF1α and HIF2α in response to hypoxia coordinate the two 
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processes that define invadopodia: 1) actin nucleation at cell membrane 
protrusions and 2) expression of proteases involved in the degradation of the 
ECM (Murphy & Courtneidge, 2011).  Moreover, these HIF-dependent increases 
in invasion and invadopodia formation are accompanied by decreases in cell 
stiffness, a physical property of cells that has been previously shown to inversely 
correlate with the invasive capacity of cells (Butcher et al., 2009; Compernolle et 
al., 2002; Cross et al., 2007; Ema et al., 1997; Flamme et al., 1997; Keith et al., 
2012; Swaminathan et al., 2011; Tian et al., 1997; 1998).  Whether these HIF-
induced alterations in cell compliance are a result of the same signaling 
pathways affecting HIF-induced invasion has yet to be determined. 
 While we examined the regulation of the SRC and MMP pathways in our 
study, HIF1α and HIF2α have been shown to regulated many other genes play a 
role in the invasive and metastatic ability of cancer.  HIF1α has been shown to 
upregulate MET expression through activation of HGF (Pennacchietti et al., 
2003; L. L. Xu et al., 2010).  Indeed, in our human melanoma cell lines we saw 
increased expression of MET only in those cells lines with activated HIF1α (data 
not shown).  It is possible that HIF1α and HIF2α are targeting multiple pathways 
to increase the invasive and metastatic phenotypes of melanoma.  It would be 
interesting to look at other HIFα targets in this system and see if their 
disregulation would have an affect. 
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D.  Clinical Applicability of Findings 
 These novel pathways could offer potential targets for melanoma patients. 
Hypoxia is associated with metastasis in many solid tumors, including melanoma.  
The data presented here suggest that HIF1α and HIF2α contribute to hypoxia-
mediated metastatic spread through the novel pathways presented.  PDGFRα, 
FAK, and SRC are kinases and are targetable by inhibitors; indeed inhibitors 
against PDGFRα (Imatinib) and SRC (Dasatinib) are already FDA approved and 
are in use for the treatment of multiple cancers. Our results imply that PDGFRα, 
FAK, or SRC inhibition in early stage melanoma patients may be beneficial as 
these pathways are critical for hypoxia-induced melanoma cell intravasation.  
However, whether activation of these pathways remains necessary for the 
maintenance of established metastases remains to be determined. 
 Preclinical studies have shown that Dasatinib decreased the proliferation 
and invasive abilities of melanoma cell lines (Eustace, Crown, Clynes, & 
O'Donovan, 2008).  Indeed, phase II clinical trials treating patients with advanced 
melanoma, stage III or IV, with Dasatinib have already occurred.  These trials 
have had mixed results, with some reporting modest activity and patient 
response and others reporting that Dasatinib has minimal activity in patients 
(excluding those with c-KIT mutations) (Kluger et al., 2011).  It is possible that in 
patients Dasatinib is not completely inhibiting SRC activity.  It may be useful to 
look at patient’s tumors post-Dasatinib treatment and see if levels of SRC 
activation (i.e. phosphorylation of Tyr416) decrease.  It may be necessary to 
create a more potent inhibitor for use in patients.  Regardless, there are currently 
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numerous clinical trials looking at the effects of Dasatinib treatment on patients 
with advanced melanoma.  The findings in this study suggest it may also be 
beneficial to treat patients with earlier stages of the disease, stage I or II, where 
the melanoma has yet to metastasize to the regional lymph nodes.   
 We have shown that SRC activation plays a role in the invasion of 
melanoma cells in vitro and have shown that its levels are decreased in less-
metastatic tumor lysates in vivo.  If patients with early stage melanoma are 
treated with Dasatinib we would hypothesize that the malignant cells would lose 
their ability to intravasate into lymph vessels and metastasis would be less likely 
to occur.  It is interesting to note that VEGFR3, the receptor of VEGF-C 
responsible for the increased lymphangiogenesis seen in metastasis, can be 
phosphorylated by binding with SRC independently of VEGF ligand binding 
(Galvagni et al., 2010; Tammela et al., 2011).  By treating early stage melanoma 
patients with Dasatinib, clinicians would not only be blocking the invasiveness of 
the malignant cell, but also blocking the creation of new lymph vessels, further 
inhibiting the metastatic spread of the disease. 
 Imatinib mesylate is an inhibitor of PDGFRα that has seen clinical success 
in treating melanoma patients when they have been screened for the presence of 
c-KIT mutations and amplifications (Carvajal et al., 2011).  Since we have shown 
that PDGFRα aids in the invasive ability of the cells, it is possible, again, that 
patients with earlier stages of melanoma, I and II with no metastasis, may also 
benefit from treatment with Imatinib.  However, treatment with Dasatinib may be 
more beneficial as it would inhibit the SRC-dependent protumorigenic effects of 
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both HIF1α and HIF2α, while Imatinib would only inhibit the HIF1α / PDGFRα 
axis. 
 The inhibition of MMPs in cancer has been difficult, with MMP-inhibitors 
(MMPIs) generally causing harmful side effects (Chaudhary, Pandya, & Ghosh, 
2013).  However, melanoma cell lines treated with Aurora-kinase inhibitors have 
decreased invasion due to the downregulation of MMP2 (L. Xie & Meyskens, 
2013) suggesting that metastatic melanoma patients may benefit from treatment 
with MMPIs.  Scientists are currently developing and testing new MMPIs and it 
will be interesting to see their affects on melanoma. 
 Melanoma patients are benefiting from new treatments that are based on 
the genetic profile of their specific tumor.  Patients with the BRAFV600E mutation 
are benefitting from treatment with Vemurafenib (Chapman et al., 2011) and 
patients with c-KIT mutations or amplifications are seeing improved disease 
progression and survival with Imatinib (Carvajal et al., 2011).  However, after 
seeing an initial response to these treatments, many patients relapse or have 
continued disease progression.  Combination therapies that not only inhibit tumor 
proliferation by blocking their growth but also inhibit the invasive ability of the 
malignant cells may be beneficial to the melanoma patients.  In this study, we 
have identified new pathways that could be possible targets in the melanoma 
invasion.  Hopefully by better understanding the disease, we will be better able to 
treat the patients and stop melanoma progression. 
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E.  Summary 
In summary, our results establish that HIF plays an active role in the 
metastatic progression of melanoma and demonstrate that HIF1α and HIF2α 
activate independent transcriptional programs, which induce invadopodia 
formation, invasion, and decrease cell stiffness.  We demonstrate in an 
autochthonous mouse model of metastatic melanoma that inactivation of Hif1α or 
Hif2α results in a significant reduction in metastases to regional lymph nodes, 
suggesting that these in vitro observations are operational in vivo. This work 
defines two novel HIF target genes, PDGFRA and FAK and is the first 
examination of the role of HIF2α in melanomagenesis.  Importantly, our studies 
for the first time directly link hypoxia, HIF1α, and HIF2α to enhanced invadopodia 
formation, adding another pathologic stimulus to the list of those currently known 
to modify invadopodia assembly and turnover.  In aggregate, our studies define 
HIF1α and HIF2α as intimately involved in the process of metastasis in malignant 
melanoma. 
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